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Summary, Conclusions and Recommendations 
 
Usage of antibiotics 
In the last year and in general over the last decade, sales of antibiotics for therapeutic use have 
increased faster than the number of livestock, whereas sales of antimicrobial growth promoters have 
gradually decreased. As the relative contribution for each therapeutic group remained practically 
unchanged, potency differences of molecules can only account for a small part of the increase in 
antibiotic consumption. The data presented here confirm the idea that the quantity and intensity of 
usage of antibiotics is increasing. Sales of quinolones and macrolides (two classes of antibiotics of 
which the usage in food animals is under debate because of potential public health risks) have shown 
the highest relative rise in 2004. 
 
An explanation used to justify the growth of the antibiotic sales is the emergence of new infectious 
diseases in pigs (PIA and Circo-virus). Nevertheless other causes may also be considered. As in other 
countries, in the Netherlands there are little economic incentives for restricted antibiotic usage. On the 
contrary, high usage of antibiotics may be rewarded with sales (industry, wholesaler and veterinarian) 
or with better economic results (farmer). As antibiotics are cheap, investments in housing and 
preventive measures may be discouraged. This effect may be reinforced by the economic position of 
the food animal production sector. Furthermore, over the use of antibiotics no justification has to be 
made to the authorities and the consumer.  
 
In Dutch broilers quinolones are used frequently, although there is a substantial variation in use 
between farms. Virtually all flocks are exposed to antibiotics; a substantial part is exposed to 
quinolones. The quinolone flumequine has the highest contribution. Use of flumequine may also select 
for resistance to fluoroquinolones (enrofloxacin and difloxacin). Prescribing quinolones by 
veterinarians is often accompanied by susceptibility testing, however the interpretations of these tests 
for the antibiotic choice remain unclear. The predominant indications for prescribing quinolones are E. 
coli-infections. 
 
In Dutch pig industry, it is assumed that most antibiotics are used in breeding facilities, whereas the 
use in fattening facilities was relatively low. As expected most antibiotics in pigs are used as group-
medication. Tetracyclines and trimethoprim/sulphonamide combinations are often used in group 
medication. The breeding facilities use a relatively high amount of broad-spectrum penicillins and 
trimethoprim/sulphonamides.  
In Dutch dairy cattle antibiotics are used less frequently compared to broilers and pigs. Fifty percent of 
the dosages are administered locally in the udder. Information on usage of antibiotics for therapeutic 
purposes in veal calves is lacking. 
 
Trends in resistance 
In Salmonella resistance in the most predominant serovars causing infections in humans (Enteritidis 
and Typhimurium) remained stable. Resistance levels and multiple resistances were substantially 
higher in S. Typhimurium than in S. Enteritidis. High level resistance to fluoroquinolones was 
observed in a serovar related to travel infections (S. Kentucky). The increase in 2003 in nalidixic acid 
resistant, ciprofloxacin decreased susceptible, S. Enteritidis, related to imported contaminated eggs, 
was not followed by a decrease in 2004.  
The prevalence of S. Java in broilers, the predominant serovar in these animals, hardly decreased in 
2004. The resistance levels in this serovar remained stable. 
 
In Campylobacter spp., highest resistance levels were observed in C. coli from pigs. Resistance levels 
to the quinolones were substantially higher in poultry, reflecting the use pattern of this antimicrobial 
class in these animals. Resistance to erythromycin was only present in C. coli and highest in strains 
from pigs. However, resistance to erythromycin was found in both endemic C. jejuni and C. coli in 
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humans and is therefore assumed to be predominantly travel related, related to consumption of 
contaminated imported products or derived by human therapeutic use of erythromycin. 
In Campylobacter the prevalence of multiple resistant strains is highest in pigs compared to poultry. A 
tendency to an increase in resistance can be observed in poultry and for amoxicillin and doxycycline. 
In pigs for most antibiotics a tendency to increase in resistance is observed. Resistance to nalidixic 
acid and ciprofloxacin is stable  
 
Data from 2004 in the current report indicate a slow overall increase in resistance in the indicator 
organisms for the commensal gut flora: E. coli and to a lesser extend enterococci. The increase is 
mainly observed in the older classes of antibiotics (amoxicillin, tetracycline, trimethoprim and 
sulphonamides). It reflects the tendency of increased usage of antibiotics in food animals since 1998. 
Resistance to formerly used growth promoters was stable or slowly decreasing (vancomycin). In spite 
of the increased use of (fluoro)quinolones in 2004, the resistance levels remained stable. 
In E. coli strains randomly isolated from broiler faeces resistance to cefotaxime increased compared to 
2003. This phenomenon is surprising because its occurrence cannot be explained by the use of third-
generation cephalosporins in these animals. Other ways of selection must exist.  
 
Comparisons of resistance data from Dutch food-animal sources for both Salmonella and 
Campylobacter, indicates than other sources than Dutch food animals contribute to infections with 
resistant organisms in humans. These sources include travel related infections, but may also include 
contaminated imported food products. Also antimicrobial therapy of human patients suffering from 
acute infectious gastro-enteritis cannot be excluded as a contributing factor. 
It stresses the necessity for The Netherlands to focus further on imported products in an attempt to 
quantify the contribution of the imported products to the resistance situation in The Netherlands. 
 
In broilers the resistance levels are higher than in pigs. The first data from veal calf products indicate 
that in veal calves the level of resistance is similar to broilers. Resistance in food products from sheep, 
goats, and biologically reared chicken are lowest. 
 
In 2004 human clinical isolates of Listeria monocytogenes, a potential zoonotic organism, were 
included in the surveillance. The vast majority of the strains were susceptible to all antibiotics. 
 
In general E. coli strains isolated from milk samples from cows suffering from mastitis were 
susceptible to the antibiotics included in the panel. The related coliform bacteria (o.a. Klebsiella, 
Enterobacter) showed a high level of resistance to amoxicillin, and to the combination with clavulanic 
acid. The S. aureus isolates tested were susceptible to most antibiotics, except a limited resistance 
level for penicillin (12.1%). MRSA was not detected in milk. The coagulase negative staphylococci 
were more resistant than S. aureus, 6.1% was mecA-positive. In the streptococci only resistance to 
erythromycin, lincomycin, pirlimycin and tetracycline was observed.  
 
It was surprising that in comparison to previous reports not all Brachyspira hyodysenteriae strains 
were resistant to tylosine (68.8%) in comparison with previous reports. All strains were susceptible to 
the pleuromutilins. 
 
Mycoplasma synoviae was susceptible to doxycycline and the macrolides, but resistance to 
enrofloxacin and difloxacin was detected. 
 
Conclusions and recommendations 
It can be concluded that therapeutic usage of antibiotics in food animals in The Netherlands steadily 
increased from 1998 till 2003 followed by a substantial increase in 2004. Determinants for the increase 
can only be speculated upon, but it seems likely that economic factors are the most important ones. 
The resistance levels in animal bacteria show a simultaneous tendency to increase. In The Netherlands 
the Royal Veterinary Association’s Antibiotics Policy Working Party published its policy in 1994. 
Rational and restrictive use of antibiotics was one of the foundations of this policy. Guidelines for 
therapy (so called formularia) have been developed and their use promoted since the mid nineties of 
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the last century. Moreover, in the nineties the Ministry of Agriculture published its policy to reduce 
the amount of veterinary medicinal products use in animals. Data in this report demonstrate that these 
policies have not totally met their goals. The constant developments in food-animal production 
warrant an evaluation of the existing policy and its implementation. At the moment Directive 
2004/28/EU on the community code relating to veterinary medicinal products is implemented in Dutch 
law. This process could be used to implement measures that stimulate more selective and restrictive 
use of antibiotics.   
 
Although a direct relation exists between usage of antibiotics in poultry and the occurrence of resistant 
food borne zoonotic pathogens causing infections in humans (C. jejuni resistant to fluoroquinolones), 
a negative effect on therapy in human patients for this diseases in the Netherlands has not been 
documented. The first choice drugs for treatment of campylobacteriosis in humans are macrolides, for 
which in C. jejuni from Dutch poultry no resistance was detected but is about 2% in patients with an 
endemic acquired infection.  
 
Based on the data in this report it can be recommended that: 
• Determinants for increased usage of antibiotics in food animals need to be examined 
• The validity and the effects of the current antibiotic policy need to be re-evaluated  
• Imported food products should be monitored for relevant resistant organisms 
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Samenvatting, Conclusies en Aanbevelingen 
 
Gebruik van antibiotica 
In het afgelopen jaar en zijn algemeenheid in het laatste decennium zijn de hoeveelheden verkochte 
antibiotica voor therapeutisch gebruik sneller toegenomen dan het aantal landbouwhuisdieren. Dit 
terwijl de hoeveelheid aan verkochte antimicrobiële groeibevorderaars gestaag afnam. Daar de 
relatieve bijdrage van iedere therapeutische klasse antibiotica ongeveer gelijk bleef, kunnen 
verschillen in potentie van gebruikte antibiotica slechts voor een klein deel hebben bijgedragen aan de 
groei in consumptie van antibiotica. De data die in dit rapport worden gepresenteerd bevestigen dat er 
een toename bestaat in de hoeveelheid en intensiteit van gebruik van antibiotica. Verkoopscijfers van 
chinolonen en macroliden (twee antibiotica klassen waarvan het gebruik in dieren ter discussie wordt 
gesteld in verband met potentiële volksgezondheidsrisico’s) gaven de grootste relatieve toename te 
zien in 2004. 
 
De toename in gebruik kan mogelijk verklaard worden door de toename in infectieziekten bij biggen 
(PIA en Circo-virussen). Echter ook andere oorzaken kunnen een rol spelen. Vergelijkbaar met andere 
landen bestaat er in Nederland weinig economische druk ten behoeve van een restrictief 
antibioticumgebruik. In tegendeel, het antibioticumgebruik geeft economische voordelen voor 
producenten en dierenartsen en omdat ze relatief goedkoop zijn ook voor de veehouder. Dit in 
tegenstelling tot duurdere huisvesting en management maatregelen. Dit effect kan worden 
gestimuleerd door de economische positie van de dierhouderij. Daarnaast speel mogelijk nog een rol 
het gebruik van antibiotica niet hoeft te worden verantwoordt aan de overheid en de consument.  
 
In Nederlandse vleeskuikens worden chinolonen frequent gebruikt, hoewel het gebruik per veehouder 
sterk varieert. Bijna alle koppels worden blootgesteld aan antibiotica; een substantieel deel van de 
koppels wordt blootgesteld aan chinolonen. Het chinolon flumequine wordt het meest frequent 
gebruikt, dit middel kan ook selecteren voor resistentie tegen de fluorochinolonen (enrofloxacin en 
difloxacin). 
 
Veterinairen schrijven chinolonen meestal pas voor na een gevoeligheidsbepaling, hoewel niet 
duidelijk is in hoeverre de interpretatie van deze testen een rol speelde bij de therapiekeuze. De meest 
voorkomende indicatie voor het toedienen van chinolonen bij pluimvee is colibacillosis. 
 
In de Nederlandse varkenshouderij wordt aangenomen dat het merendeel van het antibioticumgebruik 
plaatsvindt op vermeerderingsbedrijven, terwijl het gebruik bij mestvarkens relatief gering is. Zoals 
werd verwacht werd het merendeel van de antibiotica bij varkens als groepsmedicatie toegediend, 
waarbij tetracyclines en trimethoprim/sulfa combinaties het meest worden gebruikt. Op 
vermeerderingsbedrijven worden relatief veel breed-spectrum penicillines en trimethoprim/sulfa’s 
gebruikt. 
In Nederlands melkvee worden beduidend minder antibiotica gebruikt dan in vleeskuikens en varkens. 
De helft van alle doseringen worden toegediend in de uier. Informatie over gebruik bij vleeskalveren 
ontbreekt.  
 
Trends in resistentie 
In Salmonella bleef het resistentieniveau in de meest voorkomende serovars bij de mens (Enteritidis en 
Typhimurium) stabiel. In S.Typhimurium kwam resistentie en multiresistentie vaker voor dan in S. 
Enteritidis. High level resistentie tegen ciprofloxacin kwam voor in een serovar gerelateerd aan reizen 
naar Egypte (S. Kentucky). De toename in 2003 van nalidixinezuur resistente, ciprofloxacin 
verminderd gevoelige, S. Enteritidis, gerelateerd aan geïmporteerde eieren werd niet gevolgd door een 
afname in 2004. 
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Het voorkomen van S. Java in vleeskuikens, het predominante serovar in deze dieren, nam nauwelijks 
af in 2004. De resistentieniveaus bleven gelijk. 
 
In Campylobacter spp. werden de hoogste resistentieniveaus bereikt in C. coli uit varkens. Resistentie 
tegen chinolonen kwam meer voor in pluimveestammen, hetgeen een afspiegeling is van het gebruik 
in die dieren. Resistentie tegen erythromycine kwam alleen voor in C. coli en voornamelijk in 
stammen uit varkens. Echter erythromycine resistentie werd gevonden in endemische C. jejuni en C. 
coli stammen uit mensen en is daarom voornamelijk reisgerelateerd, gerelateerd aan gecontamineerde 
import producten of het gevolg van humane therapie. 
In Campylobacter kwamen meer multiresistente stammen voor bij varkens dan bij pluimvee. Een 
toenemende trend in resistentie werd waargenomen voor amoxicilline en doxycycline. In varkens kan 
voor de meeste antibiotica een toenemende trend in resistentie worden waargenomen. Resistentie 
tegen de chinolonen is stabiel. 
 
De data in dit rapport uit 2004 laten zien dat er een langzame toename in resistentieniveau bestaat bij 
de indicator organismen voor de commensale darmflora, E. coli en in mindere mate ook voor de 
enterokokken. Deze trend werd vooral waargenomen voor de oudere klasse antibiotica (amoxicilline, 
tetracycline, trimethoprim en sulfonamiden). Dit weerspiegelt de toename in gebruik in 
landbouwhuisdieren sinds 1998. Resistentie tegen de voormalige groeibevorderaars daalde langzaam 
of is op een stabiel niveau. In tegenstelling tot het toegenomen gebruik van chinolonen in 2004 bleven 
de resistentieniveaus stabiel. 
In E. coli stammen op aselecte wijze verzameld uit vleeskuiken feces werd een toename in resistentie 
gezien tegen cefotaxime in vergelijking met 2003. Dit is een opvallende bevinding omdat in pluimvee 
geen cefalosporinen worden gebruikt. Dit betekent dat er andere determinanten voor selectie moeten 
zijn. 
 
Het vergelijken van resistentie data van zowel salmonella’s als Campylobacter uit Nederlandse 
landbouwhuisdieren indiceert dat er andere bronnen bestaan voor infecties met resistente organismen 
bij mensen. Deze andere bronnen omvatten reisgerelateerde infecties, maar ook besmette 
geïmporteerde dierlijke producten. Ook therapie van humane gastro-enteritis gevallen kan niet worden 
uitgesloten als een factor. Het maakt duidelijk dat de noodzaak bestaat om geïmporteerde dierlijke 
producten in de monitoring te betrekken. 
 
In vleeskuikens komt in de hele lijn meer resistentie voor dan bij varkens. De eerste data van 
resistentie in vleeskalveren indiceren dat het resistentieniveau overeenkomt met die van de 
vleeskuikens. Resistentieniveaus in stammen uit kleine herkauwers, en biologische vleeskippen zijn 
het laagst. 
 
In 2004 zijn klinische isolaten van Listeria monocytogenes, een potentieel zoönotisch organisme, 
onderzocht op voorkomen van resistentie. Bijna alle onderzocht isolaten waren volledig gevoelig voor 
alle antibiotica. 
 
Voor de mastitisisolaten van melkvee geldt in zijn algemeenheid dat de onderzochte E. coli stammen 
gevoelig waren voor de geteste antibiotica. De verwante coliforme bacteriën (o.a. Klebsiella, 
Enterobacter) waren vaak resistent tegen amoxicilline en de combinatie met clavulaanzuur. De S. 
aureus stammenwaren meestal gevoelig, m.u.v. een beperkt voorkomen van penicilinne resistentie 
(12.1%). MRSA werd niet in melk aangetoond. De coagulase negatieve stafylokokken waren vaker 
resistent dan S. aureus, 6.1% was mecA-positief. In de uierstreptokokkenwerd alleen resistentie tegen 
erythromycine, lincomycine, pirlimycine en tetracycline gevonden. 
 
Het was opvallend dat de onderzocht Brachyspira hydoysenteriae  isolaten niet allemaal resistent 
waren tegen tylosine (68.8%), dit in vergelijking met eerdere publicaties. Alle stammen waren 
gevoelig voor de plueromutilins. 
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Mycoplasma synoviae was gevoelig voor doxycycline en macroliden, resistentie tegen enrofloxacin en 
difloxacin kwam wel voor. 
 
Conclusies en aanbevelingen 
Er kan worden geconcludeerd dat het therapeutische gebruik van antibiotica in landbouwhuisdieren in 
Nederland gestaag toe is genomen sinds 1998 met een piek in toename in 2004. Determinanten voor 
deze toename zijn niet met zekerheid bekend, maar het lijkt het meest waarschijnlijk dat economische 
factoren verantwoordelijk zijn. Ook de resistentieniveaus vertonen een toenemende tendens. De 
Werkgroep Veterinair Antibioticumbeleid van de Koninklijke Maatschappij voor Diergeneeskunde 
heeft haar beleid in 1994 gepubliceerd. Richtlijnen voor therapiekeuze (formularia) zijn ontwikkeld en 
hun gebruik gestimuleerd sinds het midden van de negentiger jaren van de vorige eeuw. Daarnaast 
voerde LNV in de negentiger jaren een beleid gericht op een algemene reductie van 
diergeneesmiddelengebruik. De data in dit rapport maken duidelijk dat de doelen van het voormalige 
beleid niet zijn bereikt. De constante ontwikkelingen in de veehouderij maken het noodzakelijk dat het 
bestaande beleid en de implementatie dient te worden geëvolueerd.  
Momenteel is men bezig met het implementeren van de Directive 2004/28/EU aangaande de 
‘community code’ voor diergeneesmiddelen in de Nederlandse wetgeving. Dit zou ook kunnen 
worden gebruikt voor het stimuleren van meer selectief en restrictief antibioticumgebruik. 
 
Hoewel een directe relatie bestaat tussen het gebruik van antibiotica in pluimvee en het voorkomen 
van resistente voedselpathogenen bij humane infecties (C. jejuni  resistent tegen fluorochinolonen) is 
een negatief effect op de behandeling van deze infecties bij de mens in Nederland niet 
gedocumenteerd. De eerste middelen voor behandeling van campylobacteriosis bij de mens zijn 
macroliden, waartegen in C. jejuni uit Nederlands pluimvee geen resistentie is waargenomen. 
 
Gebaseerd op de data in dit rapport kan het volgende worden aanbevolen: 
• Determinanten voor de toename in het gebruik dienen te worden onderzocht 
• De validiteit en de effecten van het huidige antibioticumbeleid dienen te worden geëvalueerd 
• Geïmporteerde dierlijke producten dienen te worden onderzocht op het voorkomen van relevante 
resistente organismen. 
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I  Usage of antibiotics in animal husbandry in the Netherlands 
 
Highlights 
In 2004 the total sales of antibiotics for therapeutic purposes in the Netherlands increased by 59.000 
kg (+15%) to 453.000 kg. Total live weight production of the most important users (pigs, broilers and 
veal calves) increased in this period by 6%. As from 1998 till 2004 the total sales of antibiotics for 
therapeutic use has increased with 127.000 kg, every year sales have grown faster than the production 
of animals. In this period the sales of antimicrobial growth promoters have declined by 175.000 kg. 
 
In Dutch poultry antibiotics for therapeutic purposes are mainly used in turkeys and broilers. The 
usage in laying hens is relatively low. In broilers quinolones are used frequently, although there is a 
substantial variation between farms. Virtually all flocks have been exposed to antibiotics; a substantial 
part has been exposed to quinolones or fluoroquinolones. Prescribing quinolones or flouroquinolones 
by veterinarians is often accompanied by susceptibility testing, however the implications of these tests 
for the antibiotic choice remain unclear. The predominant indications for prescribing quinolones and 
fluoroquinolones are E. coli-infections.  
 
Most antibiotics for therapeutic purposes in pigs are used as group-medication. Tetracyclines and 
trimethoprim/sulphonamide combinations are most often used. Most antibiotics are used in breeding 
facilities (piglets and sows). In dairy cattle antibiotics are used less frequent compared to broilers, 
turkeys and pigs.  
Information on usage of antibiotics for therapeutic purposes in veal calves is lacking. 
 
Usage of antimicrobial growth promoters (AGPs) and coccidiostats 
In the Netherlands, manufacturing, distributing and selling of animal feed containing (AGPs) and 
coccidiostats is in the hands of the feed industry and is not controlled by veterinarians. In 1998 
250.000 kg of antibiotics were used as AGPs in the Netherlands. Since cross resistance occurs 
between antibiotics formerly used as AGP and antibiotics used therapeutically for animals and 
humans, the use of antibiotics as AGP is put under pressure. Since 1999 only few antibiotics are still 
allowed and used as AGP. These are flavophospholipol (a glycolipid), avilamycin (an orthosomycin), 
salinomycin and monensin (ionophores). The latter are used both as AGP and as coccidiostat. The 
prohibition of the remaining antibiotics as from January 2006, completes the EU drive to phase out all 
AGPs from livestock production. Based on data provided by feed additive manufacturers it is 
calculated that the use of AGPs in 2004 was 75.000 kg and remained unchanged compared to 2003. 
This is a reduction of 70% compared to 1998.  
 
Usage of antibiotics as medicines for therapeutic purposes 
Total sales, provided by the pharmaceutical industry 
Since 1990 the therapeutic use of antibiotics in the Netherlands has been monitored, based on total 
sales generously provided by the FIDIN (manufacturers and importers of veterinary medicines in the 
Netherlands). In table 1 most recent data (2004) are shown. Sales from 1997 to 2004, expressed in kg, 
and the relative contribution of each therapeutic group are summarized in figure 1. In table 2 most 
recent data on numbers of Dutch livestock (2004) from the agricultural census are shown. In table 3 
live weight production1 (2004) is reported. Livestock statistics over a longer period (from 1997 to 
2004) are summarized in figure 2 and figure 3.   
                                                   
 
1 Live weight production is calculated by correcting gross indigenous product (bruto eigen productie: BEP) with 
the killing out percentage. Killing out percentages used: cattle 50%, veal calves 60%, pigs 81%, poultry 74%. 
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After a year of stable antibiotic sales in 2003, the total sales of antibiotics increased in 2004 by 59.000 
kg (+15%) to 453.000 kg (table 1). This was mainly attributed to an increase in tetracycline sales by 
42.000 kg (+19%). Expressed in percentages, the sales of quinolones and fluoroquinolones (+40%, 
2.000 kg) and macrolides (+33%, 6.000 kg) increased most rapid.  
 
Pigs, broilers and veal calves are known to be the food animals to which most antibiotics for 
therapeutic use are administered in The Netherlands. Therefore it is relevant to relate changes in 
antibiotic sales to demographic developments in these animal groups. According to the agricultural 
census in April 2004 (Statistics Netherlands, CBS) the number of pigs remained more or less 
unchanged (table 2). The Product Boards for Livestock, Meat and Eggs (PVE) however concludes, 
based on sampled data, that the pig population increased in the second half of 2004 by 3,5 %. Pig live 
weight production (based on the number of pigs) increased by 0,5 % in 2004 compared to 2003 
according to PVE. The broiler population recovered slightly from the avian influenza outbreak in the 
Netherlands in 2003, the number of broilers increased by 4,7 % (table 2), the live weight production 
increased by 15%, this is still 12% less than the live weight production in 2002. The veal calf 
population increased by 4,5% (table 2).  
 
As from 1997, total sales of antibiotics for therapeutic use have increased from 332.000 kg to 453.000 
kg in 2004 (+36 %) (figure 1). The veal calf population over this period increased by 8,6 %. The 
broiler population slightly decreased by 1,7 %. The pig population decreased over this period by 21% 
(figure 2). Because in 1997 live weight production was influenced by the outbreak of swine fever in 
the Netherlands, this is not a representative year. From 1998 the total live weight production of pigs, 
veal calves and broilers decreased by 11,2% (figure 3). It can be calculated that therapeutic antibiotic 
usage per kg live weight production in 1998 was 0,094 mg, this figure gradually increased to 0,147 mg 
in 2004 (figure 4). The total Dutch usage per kg live weight production thus calculated, cannot be 
related to the individual (pig, veal calf or poultry) industries. Apart from an intrinsic higher usage of 
antimicrobials other variables can also influence this figure. The number of piglets exported has 
increased in time, piglets are considered to be intensive users of antimicrobials compared to older 
animals. Another factor influencing this figure is that the relative contribution of veal calves has 
increased.  
 
In general the relative contribution of different therapeutic groups of antibiotics to total sales has 
remained stable over the years. In 2004 tetracyclines and trimethoprim/sulphonamide combinations 
represented 80% of the weight of total sales in antibiotics; in 1997 both classes represented 75%. 
 
 
Table 1. Total sales of antimicrobials in 2004 in the Netherlands. 
 
Therapeutic group kg of active substance in 2004 (x1000) Difference with 2003 
Penicillins/cephalosporins 45 18 % 
Tetracyclines 269 19 % 
Macrolides 24 33 % 
Aminoglycosides 9 0 % 
Quinolones and fluoroquinolones 7 40 % 
Trimethoprim/sulphonamides 93 3 % 
Other 6 - 14 % 
Total 453 15 % 
Source: FIDIN. 
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Table 2. Agricultural census in the Netherlands (2004), numbers x 1000 
 
Animal species N x 1000 in 2004 
Difference 
with 2003 (%) 
Dairy cattle 2.636 -0,9 
Veal calves 765 4,5 
Cows for fattening and grazing 366 0,0 
Cattle total 3.767 0,2 
   
Pigs for fattening (>20kg) 5.382 0,3 
Piglets 4.524 -0,4 
Pigs other 1.246 -1,1 
Pigs total 11.152 -0,2* 
   
Broilers 44.262 4,7 
Laying hens 35.668 17,0 
Broilers, breeding 5.886 -8,7 
Ducks and Turkeys 2.199 10,1 
Poultry total 88.015 8,4 
   
Sheep 1.236 4,3 
Rabbits 348 7,1 
Goats 282 2,9 
Horses and Ponies 129 2,4 
Source: Agricultural census, Statistics Netherlands (CBS). 
* Based on sampled data over 2004 PVE concludes that the pig population increased in the second half of 
2004 by 3,5 %.
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Figure 1. Usage of antibiotics for therapeutic use (active ingredient x 1000 kg) in the Netherlands and 
the usage expressed as percentages of the total use (relative use) from 1997-2004. 
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Figure 2. Developments in livestock (x 1000) in the Netherlands 1997 - 2004.  
 
 
 
 
 
 
Source: Agricultural census, Statistics Netherlands (CBS). 
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Figure 3. Live weight production in the Netherlands 1997 - 2004.  
 
 
Factors influencing live weight production: 
February 1997: outbreak of swine fever 
February 2001: outbreak of feet and mouth disease 
February 2003: outbreak of avian influenza 
 
Source: Product Boards for Livestock, Meat and Eggs (PVE) 
 
 
Figure 4. Total therapeutic usage of antibiotic (mg) per kg live weight production (pigs, poultry and veal 
calves) 1997-2004 
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 Usage of antibiotics at dairy, pig and broiler farms (continuous monitoring 
programme) 
 
The above-mentioned sales data from the pharmaceutical industry offer a general overview on 
antibiotic usage in the Netherlands. Nevertheless, to obtain more detailed information, a continuous 
programme to monitor antibiotic usage on farm level with data from the Agricultural Economics 
Research Institute (LEI) started in 2004. LEI is an institute in the Netherlands for social and economic 
research on agriculture, horticulture, fisheries, forestry and rural areas. LEI has developed the 'Farm 
Accountancy Data Network'. Various data from a random sample of agricultural and horticultural 
holdings are stored in this network. Based on this network economic data concerning veterinary 
medicines, originating from farm accountancies were obtained. LEI has also detailed information 
regarding the exposed population, in the Farm Accountancy Data Network of LEI the average number 
of animals present at a farm during a certain year is being determined accurately. This data-
combination was analysed in cooperation with the Pharmacy of the Faculty of Veterinary Medicine. It 
is difficult to obtain information from farm accountancies concerning medicines processed into animal 
feed by feed mills, as the medicine invoice may originate from the feed mill. Thus it is possible that a 
part of the in-feed medication is hiding from the observations by LEI and the data in group medication 
are underestimated. 
 
 
Table 3. Characteristics of farms and animals included 
 
Type of facility Number of 
farms in 
sample 
Type of Animal Number 
of animals 
in sample 
Percentage in sample 
(total number of 
animals in the 
Netherlands, 
LEI/CBS) 
Dairy  46 Milking cows 3.864 0,3 % (1.471.000) 
Pigs 
 
Breeding 
Fattening  
Combined 
68 
 
28 
18 
22 
Sows  
Fattening pigs (> 20 kg) 
17.875 
73.016 
1,9 %    (954.000) 
1,4 % (5.383.000) 
 
 
 
Broiler 15 Broilers 838.000 1,9%  (44.262.000) 
 
 
The data of the first year (2004) are based on 129 farms (table 3): 46 dairy farms, 68 pig farms and 15 
broiler farms. The pig farms are divided in breeding (sows and piglets), fattening and closed facilities 
(breeding and fattening). 
 
In table 4 the number of doses per animal year is presented for non-systematic treatment of dairy cattle 
(for an explanation of the unit of measurement; see box 1). The calculations are based on the average 
weight of the milking cows present at the farm, however antibiotics can also be administered to calves 
present at the farm. Milking cows are cows that have calved at least one time and are held for milk 
production or breeding purposes. Per average milking cow 1,70 times a year an antibiotic is 
administered intramammary during lactation. The combination of amoxicillin with clavulanic acid is 
used most frequent. Antibiotics to prevent infections during the dry period are administered 1,98 times 
a year. Considering a preventive treatment in all quarters, a calving interval of 420 days and a 25% 
culling rate, it can be calculated that 77% of all dry cows is treated with intramammaries. The most 
frequently used antibiotic is cloxacilline. The antibiotics used in intra-uterine therapy are tetracyclines 
and cefapirine. 
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The quantity of antibiotics used for systemic treatment in dairy cattle and their calves is presented in 
table 5. By parenteral and oral administration 2,40 dd/ay are administered. The use of 
fluoroquinolones and macrolides is limited. The relative frequent use of the third generation 
cephalosprins is related to the zero withdrawal time for milk of ceftiofur. 
 
Box 1. Antibiotics for systemic use: units of measurement for exposure (numerator) and population at risk 
(denominator) 
 
Numerator 
Exposure data of veterinary drugs are often expressed in kilogram of active substance. In order not to 
underestimate the use of high potency drugs, the number of daily dosages (dd’s) is preferably used as a unit of 
measurement. In order to calculate the number of dd’s administered, the quantity of a veterinary medicinal 
product is divided by the approved dose for that medicine. 
For example: 1 liter of Baytril ® 10% (100 mg/ml) is used in broilers; the approved dose is 10 mg/kg 
bodyweight per day. Thus 1 liter of the Baytril® solution represents 10.000 dosages to treat 1 kg of poultry 
during one day. Assuming that the average broiler weight is 1 kg, 1 liter of Baytril® solution can be used to treat 
10.000 broilers during one day. 1 liter of Baytril® represents 10.000 dd’s. 
 
Denominator 
To come to meaningful conclusions, the exposure to antibiotics must be related to the population at risk and the 
period of time over which consumption is measured. Estimations of livestock usually are a snapshot in time, 
reporting the number of animals that were present on a particular day. Assuming that the number of animals at 
risk is constant throughout the year, it could be calculated (depending on the number of animal housings) how 
many animals were at risk of being exposed to antibiotics during a certain period of time (in this case during one 
year).  
For example: one pig is present and the antibiotic exposure was measured during one year. It is assumed that, 
although this pig was slaughtered within 6 months, there was one pig present throughout the entire year and that 
therefore the potentially exposed population (the population at risk) was one pig year (or 365 pig days). To 
report the population at risk, the words Animal Years (ay) or Animal Days (ad) are used. 
 
 
As demonstrated in table 6, the antibiotic usage in pig farm is substantially higher compared to dairy 
cattle (table 4). Exposure to antibiotics is concentrated in breeding facilities rather than in fattening 
facilities. Furthermore, in the breeding facilities the number of daily dosages is calculated over the 
total average weight of sows and piglets (and other pigs) present at a farm. We suppose however that 
to piglets antibiotics are administered more intensively than to sows. The total average weight of the 
piglets present at a farm amounts to some 15 - 20% of the weight of the sows present. Taking this into 
consideration, the real exposure of piglets to antibiotics will be higher as calculated here. In particular 
trimethoprim/sulphonamide combinations and penicillins are used more intensively in breeding 
facilities (figure 5). This may be related to usage in weaning piglets. Overall, tetracyclines are used 
often whereas the use of quinolones or fluoroquinolones is limited.  
 
Antibiotic usage in broiler farms is presented in table 7. Broilers in this sample used 16, 3 daily 
dosages per animal year. This equals to 0,04 dosages per day. During their approximately 40-day live 
the average broiler in this sample was medicated with antibiotics for therapeutic purposes during 2 
days. Tetracyclines (33%) as well as quinolones and fluorquinolones (22%) and 
trimethoprim/sulphonamide combinations (20%) are used relatively frequent. Fluoroquinolones 
(enrofloxacin and difloxacin) are used in 1,5 % of all daily dosages. Antibiotic usage (figure 6) and 
quinolone usage (figure 7) was also measured at flock level. Virtually all flocks (48 out of 51) 
investigated (94 %) were exposed to antibiotics. In the sample 12 flocks out of 51 flocks (24%) were 
exposed to quinolones or fluoroquinolones. 
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Table 4. Number of daily dosages per animal year (dd/ay) administered in dairy cattle (non-systemic use), 
continuous monitoring programme 
 
Therapeutic Group Intramammary use in lactating cows dd/ay 
Cephalosporins Cefoperazone 0,16 
 Cefquinome 0,27 
 
Lincosamides 
 
Pirlimycine 0,02 
Combinations Dihydrostreptomycin-benzylpenicillin-nafcillin 0,17 
 Neomycin-benzylpenicillin 0,02 
 Amoxicillin-clavulanic acid 0,71 
 Ampicillin-cloxacillin 0,09 
 Lincomycin-neomycin 0,25 
   
 Total milking cows 1,70 
 
 
Therapeutic Group Intramammary use in dry cows dd/ay 
Penicillines Cloxacillin 0,80 
   
Combinations Dihydrostreptomycin-benzylpenicillin-nafcillin 0,31 
 Neomycin-benzylpenicillin 0,38 
 Ampicillin-cloxacillin 0,49 
   
 Total dry cows 1,98 
 
 
Therapeutic Group Intra-uterine use in cows dd/ay 
Cephalosporins Cefapirin 0,06 
   
Tetracyclines Oxytetracycline 0,13 
 Tetracycline 0,01 
   
 Total intra-uterine 0,20 
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Table 5. Number of daily dosages per animal year (dd/ay) administered in dairy cattle and their calves 
(oral and parenteral administration), continuous monitoring programme 
 
Therapeutic group Active substance (administration) dd/ay 
Cephalosporins Cefquinome 0,04 
 Ceftiofur 0,27 
  0,31 
   
Penicillines Benzylpenicillin 0,33 
 Ampicillin 0,09 
  0,42 
   
Macrolides Erythromycin 0,03 
 Tylosin 0,01 
  0,04 
   
Fluoroquinolones Danofloxacin 0,01 
 Enrofloxacin 0,04 
  0,05 
   
Sulphonamides and trimethoprim Trimethoprim-sulfadiazine 0,11 
 Trimethoprim-sulfadoxine 0,12 
 Trimethoprim-sulfamethoxazole 0,01 
 Sulfadimidine 0,01 
  0,25 
   
Tetracyclines Doxycycline 0,04 
 Oxytetracycline 0,53 
  0,57 
   
Others Florfenicol 0,01 
 Lincomycin 0,03 
 Colistin 0,28 
  0,32 
   
Combinations Ampicillin-colistin 0,01 
 Amoxicillin-colistin 0,01 
 Dihydrostreptomycin-benzylpenicillin 0,07 
 Lincomycin-spectinomycin 0,01 
 Neomycin-benzylpenicillin 0,32 
  0,42 
   
 Total 2,38 
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Table 6. Average number of daily dosages per animal year (dd/ay) administered as group medication or 
individual (ind.) medication in three types of pig farms, continuous monitoring programme 
 
Therapeutic group Active substance Fattening facilities Breeding facilities (sows and piglets) 
Combined 
facilities 
(breeding and 
fattening) 
  Group* Ind. Group* Ind. Group* Ind. 
Penicillines Benzylpenicillin - 0,24 - 0,61 - 0,53 
 Ampicillin - 0,18 0,27 0,54 0,89 0,26 
 Amoxicillin 0,01 0,01 1,72 0,12 1,16 0,06 
 Total 0,01 0,43 1,99 1,27 2,05 0,85 
        
Cephalosporines Cefquinome - - - 0,01 - 0,01 
 Ceftiofur - - - 0,01 - 0,03 
 Total - - - 0,02 - 0,04 
        
Macrolides and Tilmicosin 0,02 - 0,23 - 0,22 - 
lincosamides Tylosin 0,55 0,04 0,06 0,01 0,45 0,01 
 Lincomycin 0,01 - - - - - 
 Total 0,58 0,04 0,29 0,01 0,67 0,01 
        
Quinolones Flumequine - - 0,22 - - - 
 Enrofloxacin - 0,01 - 0,02 - - 
 Total - 0,01 0,22 0,02 - - 
        
Sulphonamides Tmp-sulfadiazine 0,64 - 4,46 0,12 1,20 0,01 
and trimethoprim Tmp-sulfadoxine - - - 0,18 - 0,03 
 Tmp-sulfamethoxazole 0,61 - 2,61 0,01 2,95 - 
 Total 1,25 - 7,07 0,31 4,15 0,04 
        
Tetracyclines Doxycycline 3,46 - 4,57 - 7,39 - 
 Oxytetracycline 6,73 0,47 4,40 0,26 4,55 0,29 
 Total 10,19 0,47 8,97 0,26 11,94 0,29 
        
Aminoglycosides Gentamicin - - 0,03 0,01 0,05 - 
 Total - - 0,03 0,01 0,05 - 
        
Combinations Lincomycin-spectinomycin 0,05 - 0,54 0,02 0,01 - 
 Amoxicillin-colistin 0,07 0,02 0,04 0,09 - 0,07 
 Neomycin-benzylpenicillin - - - 0,02 - 0,10 
 Dihydrostreptomycin-benzylpenicillin - 0,21 - 0,74 - 0,70 
 Total 0,12 0,23 0,58 0,87 0,01 0,87 
        
Others Tiamulin - - 0,02 - - - 
 Colistin 0,13 - 1,57 - 0,36 - 
 Florfenicol - 0,01 - 0,03 - 0,03 
 Total 0,13 0,01 1,59 0,03 0,36 0,03 
        
Total  12,28 1,19 20,74 2,79 19,23 2,13 
 
* It is possible that a part of the in-feed medication is hiding from the observations by LEI and therefore the data 
on group medication in pigs may be underestimated. 
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Table 7. Average number of daily dosages per animal year (dd/ay) administered in broiler farms, 
continuous monitoring programme 
 
Therapeutic group Active substance dd/ay 
Penicillines Ampicillin 0,41 
 Amoxicillin 2,60 
 Total 3,01 
   
Macrolides and lincosamides Tylosin 0,73 
   
Quinolones Enrofloxacin 0,25 
 Flumequine 3,40 
 Total 3,65 
   
Sulphonamides and trimethoprim Trimethoprim-sulfachloorpyridazine 1,57 
 Trimethoprim-sulfamethoxazole 1,69 
 Sulfadimidine 0,07 
 Total 3,33 
   
Tetracyclines Doxycycline 4,76 
 Oxytetracycline 0,84 
 Total 5,60 
   
Aminoglycosides Neomycin 0,45 
   
Combinations Lincomycin-spectinomycin 0,04 
   
Total  16,81 
 
 
Figure 5. Use of antibiotics for therapeutic use in different types of pig farms 
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Figure 6. Antibiotic usage in broilers (number of daily dosages per animal year (dd/ay)) per  
flock  
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Figure 7. Quinolone usage in broilers (number of daily dosages per animal year (dd/ay)) per flock 
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Usage of antibiotics, specifically quinolones and fluoroquinolones, in poultry 
 
Although the use of quinolones and fluoroquinolones in poultry is under debate, little is known about 
the quantity and the way antibiotics are used in these animals. Results from a study on antibiotic usage 
usage in poultry in 2004, are presented here. Antibiotic prescription data from 7 volunteering 
veterinary practices, specialized in poultry were sampled and analyzed. Livestock from these practices 
amounted to 13,3 million animals in 345 farms (15% of the total Dutch poultry population). The 
period examined was January 2004 till October 2004. In this period antibiotics were prescribed 1525 
times by the participating practitioners.  
 
In table 8 the number of doses per animal year is presented (for an explanation of the unit of 
measurement: see box 1). As expected, antibiotics were prescribed most frequently to broilers and 
turkeys. The intensity of antibiotic usage in turkeys and broilers is comparable. Turkeys however live 
longer and consequently individual turkeys are exposed more frequently to antibiotics.  
 
Broilers were prescribed 21,6 daily dosages per animal year (dd/ay). This equals to 0,06 daily dosages 
per animal day (dd/ad). During their approximately 40-day live the average broiler in the sample was 
medicated with antibiotics for therapeutic purposes during 2 - 3 days. In this sample the most 
commonly used antibiotics in broilers were tetracyclines (35 % of the dosages) and the first generation 
quinolone flumequine (34 %). In broilers the fluoroquinolones (enrofloxacin and difloxacin) were 
used in 2 % of the dosages. A notable variation in antibiotic usage was found between farms. Six 
broiler farms did not use any antibiotics, whereas the highest user was 74 dd/ay. No relation was found 
between the number animal in broiler farms and the amount of antibiotics prescribed (figure 8). 
Assuming that quinolones are used during three consecutive days and that, if broilers are treated with 
quinolones, they are treated only once in a life-time, it can be calculated that out of 100 flocks 
slaughtered, to 27 of them quinolones or fluoroquinolones were administered.  
 
In turkeys, tetracyclines are commonly used (73 % of the dosages). As flumequine is not approved for 
use in turkeys, its use is limited (0,3% of the total number of dosages). Due to the high price-level the 
use of fluoroquinolones in turkeys is also low (0,7%). The amount of antibiotics prescribed to laying 
hens is limited. In turkeys and broilers the withdrawal time only has to be considered before slaughter. 
In laying hens every antibiotic treatment has economic consequences, since the eggs cannot be used in 
human consumption during the withdrawal time. The way laying hens are housed (battery cages, free-
range system, aviary housing system and organic poultry farming) did not have a significant influence 
on antibiotic usage.  
 
The indications for prescribing quinolones and fluoroquinolones in poultry are reflected in figure 9. 
Most frequent reasons for prescribing are E. coli-infections (i.e. yolk sac infections, peritonitis, 
synositis, airway infections, infections of the locomotion system). When prescribing quinolones or 
fluoroquinolones in poultry, in 71% of the cases a susceptibility test was performed. The quality and 
judgment of the test, as well as the follow up actions are not evaluated.  
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Table 8. Average number of daily dosages per animal year (range),  
 
 
 Turkeys 
Laying hens 
(consumption 
eggs) 
Laying hens 
(hatching 
eggs) 
Breeding 
animals broilers 
Penicillines (broad spectrum) 2,4 (0 – 9,6) 0,1 (0 - 3,4) 0,4 (0 – 27,7) 1,3 (0 – 10,6) 2,6 (0 – 12,1) 
Macrolides 2,2 (0 – 7,7) 0 (0 – 2,0) 0 (0 – 0,1) 0,0 (0 – 1,1) 1,2 (0 – 9,3) 
Third generation quinolones 
(enrofloxacin and difloxacin) 0,7 (0 – 2,0) 0 (0 - 0,1) 0,1 (0 – 3,6) 0,1 (0 – 2,6) 0,5 (0 – 13,0) 
First generation quinolones 
(flumequine) 0,3 (0 – 2,9) 0,2 (0 – 6,8) - 0,2 (0 – 4,6) 7,3 (0 –51,1) 
Sulfonamides 0,7 (0 – 4,48) 0 (0 - 2,0) - - 0,1 (0 – 4,6) 
Sulphonamides and 
trimethoprim 0,0 (0 – 0,15) 0 (0 –0,5) - 0,6 (0 – 9,3) 1,8 (0 – 24,6) 
Tetracyclines 18,2 (0 – 42,3) 0,7 (0 – 4,6) 1,3 (0 – 20,7) 0,8 (0 – 12,6) 7,5 (0 – 12,1) 
Aminoglycosides 0,5  (0 – 4,3) 0,4 (0 – 27,7) 1,0 (0 – 14,6) 0,1 (0 – 3,5) 0,4 (0 – 9,8) 
Polymyxines - - - - 0,0 (0 – 2,0) 
Spectinomycin in 
combination with clindamycin 
and lincomycin 
- 0 (0 – 0,1) - - 0,1 (0 – 5,4) 
Total 25,0 1,4 2,8 3,1 21,6 
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 Figure 8 Relation between farm-size and antibiotic usage  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Indications for quinolone prescriptions in poultry 
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II Resistance data 
 
In this chapter susceptibility test results are presented as determined in 2004 for the food-borne 
pathogens Salmonella, Campylobacter and Escherichia coli O157, the food-borne commensal 
organisms E. coli, Enterococcus faecium and E. faecalis, Listeria monocytogenes the bovine mastitis 
pathogens Staphylococcus aureus, Streptococcus uberis, S. dysgalactiae, E. coli and coliform bacteria, 
poultry pathogens Mycoplasma synoviae and pig pathogens Brachyspira hyodysenteriae.  
MIC-data on the bovine respiratory disease pathogens Pasteurella multocida and Mannheimia 
haemolytica will not be included in this report because the number of strains isolated in 2004 was too 
small. 
Food-borne pathogens 
Salmonella spp. 
In this chapter resistance percentages are presented on salmonella’s isolated from humans with clinical 
infections, food-animals and their products, as potential sources for distribution to humans via the food 
chain, and animal feeds as potential source for food-animals and their products.  
 
Highlights 
In 2004 S. Enteritidis was still  the most prevalent serovar in humans, but the incidence decreased 
compared to 2003. S. Typhimurium was the second most prevalent serovar in humans. Pigs and cattle 
were the most important animal sources of S. Typhimurium, and layers (eggs) of S. Enteritidis. In 
broilers S. Java was isolated most frequently. In these animals S. Enteritidis and S. Typhimurium 
constitute only a small fraction of all salmonella’s. 
Resistance levels and multiple resistances were substantially higher in S. Typhimurium than in S. 
Enteritidis. Resistance to ciprofloxacin was incidentally detected in S. Kentucky strains isolated from 
human patients (also detected in 2002 and 2003). These strains were related to travel to Egypt and not 
to Dutch food-animals. Resistance to nalidixic acid was more commonly present in S. Enteritidis and 
S. Typhimurium isolated from humans than from animals. It was predominantly present in S. 
Enteritidis (Pts1, 6a, and 8), S. Hadar, S. Virchow and S. Java and only rarely in S. Typhimurium. It 
can be concluded that nalidixic acid resistant strains of S. Enteritidis and S. Typhimurium isolated 
from humans either originate from imported animal products or from travel related infections. Therapy 
of humans may have contributed as well. 
The prevalence of S. Java in broilers slightly decreased in 2004. However, at retail the proportions of 
poultry meat products contaminated with S. Java remained at the same high level. The resistance levels 
in this serovar remained stable. 
 
For the purpose of antimicrobial resistance surveillance in Salmonella spp., it is essential to include 
information on the relative importance of the different serovars in humans and food-animals and 
animal feeds (table 9). In 2004, like in former years, S. Typhimurium and S. Enteritidis were by far the 
most frequently isolated serovars of Salmonella in humans in The Netherlands. In pigs S. 
Typhimurium and in cattle S. Typhimurium and S. Dublin were the most prevalent serovars. In poultry 
a difference existed in prevalence of Salmonella spp. between broilers and layers. In broilers S. 
Paratyphi B var. Java (S. Java) and S. Infantis, and in layers S. Enteritidis and S. Senftenberg were the 
predominantly isolated serovars. 
Travel contributed from 0% to 50% of the cases of human salmonellosis depending on the 
sero/phagetype. Among the most frequently isolated human serovars travel contributed substantially 
more to the incidence of S. Enteritidis than for S. Typhimurium.  
 In 2004 the incidence of S. Enteritidis slightly decreased again after the sudden increase in 2003 
related to the increase of imported eggs. The occurrence of S. Java in broilers decreased.  The increase 
in prevalence of S. Infantis and S. Senftenberg in layers in 2003 is followed by a decrease for S. 
Infantis in 2004 and a substantial further increase in prevalence for S. Senftenberg. However, this is 
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not relevant for public health because Dutch layers are not the source for infections with S. 
Senftenberg.  
 
Table 9. Most prevalent Salmonella sero-, and phagetypes isolated in 2004 (2003 between brackets) from 
humans, pigs, poultry, broilers and layers2 and the % travel related infections in 2003 – 2004. 
  Humans Pigs Cattle Poultry Broilers Layers 
Total number sent to RIVM 1626 388 187 568 355 141 
Sero/phage type % Travel % of the total sent to RIVM in 2004 (2003 data between brackets) 
Typhimurium  2% 28.5 47.9 15.0 3.5 3.9 2.8 
DT104 2% 6,5(7,4) 11,8(17,3) 4,8(8,4) 0.9 1.1 0.7 
ft 507  1% 6.4 12,4(9) 3.2 0.2 0.3 -- 
ft 508  2% 1,7(1,1) 2,3(1,1) -- 0.5 0.8 -- 
ft 510  7% 1.4 1.5 0.5 -- -- -- 
ft 90  0% 0.1 4,1(0) 1.1 -- -- -- 
ft 655  3% 1.1 --(2,9) 0.5 -- -- -- 
ft 295  0% 0.2 --(0,7) --(1,7) -- -- -- 
ft 350  0% 0.1 1,5(0) -- -- -- -- 
Enteritidis  9% 47,2(55,2) -- -- 9.5 5.9 22.0 
Pt 4  7% 13,8(19) -- -- 3.9 2.3 8,5(12,6) 
Pt 1  17% 5,2(7,9) -- -- 0.2 0,3(1) --(0,8) 
Pt 21  7% 8,7(12,2) -- -- 1,6(1,1) 2(1) 1,4(0,8) 
Pt 6  7% 3,9(2,8) -- -- 0.9 -- 3,5(5,9) 
Pt 7  14% 0.2 -- -- 1,2(0,3) 0.8 2,8(1,7) 
Pt 8  7% 6,2(4,6) -- -- 0.4 0.3 0,7(1,3) 
Pt 14b 14% 0,9(2,4) -- -- 0.4 -- 1.4 
Pt 6a  20% 1.8 -- -- -- -- -- 
Paratyphi B, var, Java 0% 0.2 0.3 -- 23,6(40,1) 34,6(55,3) --(3,4) 
Infantis  16% 1.4 1.0 -- 8,1(29,8) 7,6(18,1) 5,7(34) 
Dublin  0% 0.4 0.3 44.9 -- -- -- 
Senftenberg  29% 0.2 0.5 -- 9,5(3,3) 2.8 25,5(13,9) 
Derby  7% 0.6 13,4(7,9) 2.1 1,8(0,5) 2,3(1) 0,7(0) 
Virchow  34% 0.8 -- 1.1 5.8 2.8 12.1 
Livingstone  6% 0.4 1.5 -- 1.1 1.1 -- 
Mbandaka  8% 0.6 0.3 1.6 4,9(2,2) 4,5(1,8) 2.1 
Anatum  30% 0.4 7.7 8.0 0.5 0.6 -- 
Agona  23% 0.5 0.5 -- 2,8(1,5) 1.7 5.0 
Brandenburg  0% 1.2 2.3 2.7 0.5 0.3 1.4 
Goldcoast  0% 0.8 0,3(6,1) 1,1(0) 0.2 -- 0.7 
Weltevreden  50% 0.1 4,4(0) 5,9(0) 0.4 -- -- 
Gallinarum  -- -- -- -- 2,1(0,3) 0.3 5,7(1,3) 
Hadar  13% 1.0 -- -- 1,9(0,4) 2,3(0,6) 1,4(0,4) 
Montevideo  18% 0.4 0.0 0.5 1.1 1.1 0.7 
Panama  11% 0.5 4,6(1,1) -- 0.2 0.3 -- 
Lexington  -- -- 0.3 6,4(0) -- -- -- 
Rissen  -- -- 4,1(0,4) 0.5 0.5 -- 1.4 
London  5% 1.0 0.5 0.9 1.4 -- 0.3 
Blockley  0% 0.1 -- -- 2,8(0,1) 3,7(0) -- 
Indiana  0% 0.2 -- -- 1.1 1.1 0.7 
Albany  33% 0,1(0) -- -- 2,1(0) 2,8(0) 1,4(0) 
                                                   
 
2 Source: Report on trends and sources of zoonotic agents in the EU, 2004, The Netherlands 
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  Humans Pigs Cattle Poultry Broilers Layers 
Total number sent to RIVM 1626 388 187 568 355 141 
Sero/phage type % Travel % of the total sent to RIVM in 2004 (2003 data between brackets) 
Corvallis  13% 0,4(0,1) -- -- 1,6(0) 2,5(0) 0.0 
Heidelberg  4% 0.8 -- -- --(0,8) --(0,6) --(1,3) 
Newport  21% 0.8 1,5(0) 0.5 0.2 0.3 -- 
Thompson -- -- -- 1,1(0) 0.5 0.3 1,4(0) 
Table 1 continued        
(Para)Typhi (A B C)  35% 1.9 -- -- -- -- -- 
Kentucky  50% 1,3(0,3) -- 0.5 0.2 0.3 -- 
Give 0% 1(0,1) -- -- -- -- -- 
Other serovars  7.2 8.6 7.2 12.1 16.9 9.0 
Typing results of the Dutch Salmonella Reference Laboratory (RIVM, Bilthoven). Isolates are from different 
sources and programs. Poultry: all chicken categories together; Broilers: including chicken products; Layers: 
including reproduction animals and eggs.  
 
 
Table 10. MIC distribution (in %) for all salmonella’s (N = 2195) tested for antibiotic susceptibility in 
2004. 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
 
Table 10 presents MIC-distributions and resistance percentages of all salmonella’s tested for 
susceptibility in 2004. Highest levels of resistance were observed for sulphamethoxazole, tetracycline 
and amoxicillin and to a lesser extend nalidixic acid, trimethoprim and chloramphenicol.  
Seven cefotaxime resistant, ESBL suspected strains were found, which was less than in 2003 (n = 13). 
These isolates belonged to the following serovars: 1 S. Braenderup, 2 S. Paratyphi B var. Java, and 3 S. 
Infantis from poultry and 1 S. Enteritidis Pt 14b isolated from a human patient. Except the two S. Java 
strains they were susceptible to the other antibiotics included in the test. It is the third consecutive year 
that ESBL-positive S. Java strains were detected.  
The S. Braenderup and S. Infantis were also resistant to clavulanic acid; S. Infantis was also resistant 
to cefoxitin and is therefore AmpC-suspected. The two S. Java strains showed characteristics of CTX-
M (cefotaxime R, ceftazidime I), the other strains showed a typical ESBL-phenotype (cefotaxime and 
ceftazidime R, a synergistic effect of the antibiotics combined with clavulanic acid and cefoxitin S). 
The beta-lactamase genes in these salmonella’s and in those detected in E. coli will be typed 
MIC distribution (µg/ml) 
Total 2004 
0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 
R% 
Amoxicillin    21.2 62.0 1.7      15.1    15.2 
Cefotaxim  90.3 8.3 1.0 0.05    0.1 0.2      0.3 
Imipenem  84.1 14.9 0.9            0.0 
Gentamicin   32.1 56.8 10.0 0.7   0.2 0.1 0.1     0.5 
Neomycin     90.2 8.2 0.6   0.1 0.1 0.5 0.3   1.0 
Tetracycline    0.1 17.6 62.5 3.8 0.3 0.3 4.9 3.1 7.3    15.6 
Sulphameth.        32.5 48.7 2.4 0.05   0.1 16.2 16.3 
Trimethoprim    85.6 5.7 1.0 0.1  0.1   7.6    7.7 
Ciprofloxacin 91.4 2.9 3.6 1.5 0.4   0.23 0.05       0.3 
Nalidixic Acid      3.7 79.1 8.3 0.8 0.1  0.6 7.4   8.2 
Chloramphenicol       6.5 79.7 6.6 0.2 0.1 0.4 6.5   7.2 
Florfenicol      0.7 73.2 19.0 1.1 4.7 0.7 0.4 0.14   6.0 
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molecularly in co-operation with dr. Ernesto Liebana, Veterinary Laboratories Agency, Weighbridge, 
UK. This data will be reported separately. 
 
Eleven gentamicin resistant strains, and twenty two neomycin resistant strains were found, the 
majority isolated from human patients. Four of the gentamicin resistant strains were also high level 
ciprofloxacin resistant (S. Kentucky). 
 
Six ciprofloxacin resistant S. Kentucky strains (MIC ≥ 8 µg/ml) were isolated from human patients (in 
2002 and 2003 also ciprofloxacin resistant S. Kentucky’s were isolated from human patients). These 
strains are related to travel to Egypt. Obviously clonal spread of a fluoroquinolone resistant S. 
Kentucky in Egypt resulted in human salmonella infections in tourists.  
 
One hundred seventy nine (in 2002 168 and in 2003 271) nalidixic acid resistant strains were found. 
These strains all showed reduced susceptibility to ciprofloxacin (MIC ≥ 0,125 µg/ml). In 2004 4 S. 
Corvallis strains from human patients demonstrated an atypical quinolone resistance phenotype. These 
strains showed reduced susceptibility to ciprofloxacin (MIC 0.5 µg/ml) but were susceptible to 
nalidixic acid (MIC 16 µg/ml). The genetic basis of this phenotype is yet unknown. 
 
Sixteen fully susceptible S. Newport strains were found, one isolated from poultry, thirteen from 
human patients and two from soy products. 
 
 
Table 11. Resistance percentages of the ten most prevalent Salmonella serovars isolated in The 
Netherlands in 2004. 
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Amoxicillin 3.0 47.6 1.1 2.7 8.9 13.2 72.2 17.9 0 20.0 5.0 
Cefotaxime 0.2 0 0 0 0 5.7 5.6 0 0 0 0 
Imipenem 0 0 0 0 0 0 0 0 0 0 0 
Gentamicin 0 0.2 0 0 0 0 0 0 3.8 0 0 
Neomycin 0.2 1.1 0 0 0 1.9 2.8 0 0 0 0 
Tetracycline 0.3 55.4 1.1 1.3 7.1 3.8 5.6 35.7 0 12.0 15.0 
Sulphamethox. 0.8 50.7 10.3 4.0 12.5 7.5 72.2 42.9 19.2 20.0 5.0 
Trimethoprim 0.3 15.4 1.1 4.0 7.1 5.7 100 42.9 19.2 20.0 5.0 
Ciprofloxacin 0 0 0 0 0 0 0 0 0 0 0 
Nalidixic acid 12.2 3.0 3.4 0 0 5.7 36.1 7.1 0 80.0 0 
Chloramphenicol 0.2 28.0 9.2 1.3 0 1.9 0 7.1 0 0 0 
Florfenicol 0 27.6 0 0 0 0 0 3.6 0 0 0 
            
% fully sens 85% 35% 86% 96% 84% 81% 0% 43% 81% 12% 85% 
%R to 1 an 14% 14% 3% 0% 5% 8% 17% 11% 0% 64% 10% 
%R to 2 ant 1% 4% 9% 1% 2% 6% 11% 14% 15% 4% 0% 
%R to 3 ant 0% 14% 0% 1% 9% 2% 39% 21% 4% 8% 0% 
%R to 4 ant 0% 4% 1% 0% 0% 0% 28% 7% 0% 4% 5% 
%R to >4 ant 0% 28% 0% 1% 0% 4% 6% 4% 0% 8% 0% 
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In table 11 resistance percentages are presented for the most prevalent serovars isolated in The 
Netherlands in 2004. The highest resistance levels are observed in S. Typhimurium, S. Java and S. 
Derby, the serovars also harbouring the highest percentages of multiple resistant isolates.  
S. Enteritidis 
In table 12 resistance percentages for S. Enteritidis and it most prevalent phage types are presented. In 
The Netherlands, human infections caused by S. Enteritidis are predominantly related to the 
consumption of raw shell eggs. In Dutch broilers and broiler products the prevalence of S. Enteritidis 
is low (Tables 9 and 15). The difference in resistance profile of strains from human infections and 
Dutch poultry indicates that other sources of infection exist. In 2004 from human infections 75 
nalidixic acid-resistant strains were isolated, predominantly Pt1 (46%) and to a lesser extend Pt8 
(13%) and Pts 4 and 6a (11%). In Dutch poultry no nalidixic acid-resistant strains were found. 
 
Table 12. Resistance percentages of S. Enteritidis and phagetypes 4, 21, 8, 1, 6, 6a, 16a and 14b isolated 
from different sources in 2004. 
 S. Enteritidis Phage types 
 Human (461) 
Dutch 
poultry 
(27) 
pt4 
(205) 
pt21 
(125) 
pt8 
(77) 
pt1 
(71) 
pt6 
(54) 
pt6a 
(22) 
pt14b 
(15) 
Amoxicillin 3.0 11.1 1.5 0 0 2.8 0 40.9 6.7 
Cefotaxime 0.2 0 0 0 0 0 0 0 6.7 
Imipenem 0 0 0 0 0 0 0 0 0 
Gentamicin 0 0 0 0 0 0 0 0 0 
Neomycin 0.2 0 0 0 0 0 0 4.5 0 
Tetracycline 0.4 0 0 0 0 1.4 1.9 0 0 
Sulphamethox 0.7 3.7 0.5 0 0 1.4 1.9 9.1 0 
Trimethoprim 0.2 0 0 0 0 0 1.9 4.5 0 
Ciprofloxacin 0 0 0 0 0 0 0 0 0 
Nalidixic acid 14.1 0 4.4 1.6 13.0 50.7 5.6 36.4 6.7 
Chloramphenicol 0.2 0 0 0 0 0 0 4.5 0 
Florfenicol 0 0 0 0 0 0 0 0 0 
          
% fully sens 85% 88% 94% 98% 87% 48% 94% 27% 91% 
%R to 1 ant 13% 12% 6% 2% 13% 49% 4% 55% 5% 
%R to 2 ant 1% 0% 0% 0% 0% 1% 0% 9% 5% 
%R to 3 ant 1% 0% 0% 0% 0% 1% 0% 9% 0% 
%R to 4 ant 0% 0% 0% 0% 0% 0% 2% 0% 0% 
%R to >4 ant 0% 0% 0% 0% 0% 0% 0% 0% 0% 
 
 
 
Multiple resistance is not very common in S. Enteritidis. Incidentally multiple resistant strains were 
observed in PT1, Pt6, Pt6a and Pt14b. 
Trends in resistance are limited to nalidixic acid resistance in human isolates (Fig. 10). The observed 
increase in 2003 related to increase of imported eggs due to the influenza outbreak, has not been 
followed by a decrease in 2004. 
 
It can be concluded that nalidixic acid resistant strains of S. Enteritidis isolated from humans either 
originate from imported eggs or from travel related infections. Therapy of humans may have 
contributed as well. 
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Figure 10. Trends in resistance percentages of S. Enteritidis isolated from humans and poultry 
(predominantly from Dutch layers and reproduction animals, whilst poultry meat is of mixed Dutch and 
imported origin) from 1999 - 2004.
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S. Typhimurium 
Resistance percentages of S. Typhimurium in 2004 were strongly determined by the presence of multi 
drug resistant phage types DT104, Ft 510, Ft 507 and Ft 508, being among he predominant phage 
types of S. Typhimurium, both in food-animals and in humans (table 13).  
 
In 2003 thirteen nalidixic acid resistant S. Typhimurium isolates were found, in 2004 fourteen. Seven 
were DT104, three were Ft 507, two Ft 12, and one Ft 508 and 510, respectively. Thirteen of these 
strains were isolated from human patients; one DT104 was isolated from pig faeces. All nalidixic acid 
resistant isolates demonstrated reduced susceptibility to ciprofloxacin but were not high-level 
ciprofloxacin resistant.  
 
Resistance levels and multiple resistances were substantially higher in S. Typhimurium than in S. 
Enteritidis (table 5, Fig. 11). Approximately 50% of the strains were resistant to three or more 
antibiotic classes in poultry and pig isolates. In humans isolates this was 33% and cattle the level of 
multiple resistance was highest (61%).  
 
Trends in resistance in S. Typhimurium are difficult to determine in all sources (Fig. 12) because of 
the influence of the presence of multiple resistant clones and the relatively small number of isolates 
from cattle and poultry. Specifically when the total numbers of strains per year are relatively small the 
variability in the resistance percentages is high (eg. in poultry). In 2004 in pigs an increase was 
observed in resistance to amoxicillin, tetracycline, sulphamethoxazole and the fenicols, 
chloramphenicol and florfenicol, as a result of the clear increase in proportion of DT104 isolated from 
pigs, 35% in 2004 compared to 19% in 2003. 
In human isolates the level of nalidixic acid resistance (3.9%) was higher than in animal isolates and 
cannot be explained by the proportion of DT104 present. Therefore also in S. Typhimurium either 
imported animal products, travel or human therapy may have contributed to nalidixic acid resistance.. 
 
 
Table 13.  Resistance percentages of S. Typhimurium and phage types DT104, Ft 507, FT510, Ft 508 and 
Ft401 isolated from different sources in 2004. 
 Human (334) 
Pigs 
(77) 
Cattle 
(13) 
Poultry 
(9) 
DT104 
(129) 
ft507 
(121) 
ft510 
(32) 
ft508 
(31) 
ft401 
(20) 
Amoxicillin 49.1 51.9 53.8 44.4 89.9 47.9 25.0 48.4 70.0 
Cefotaxime 0 0 0 0 0 0 0 0 0 
Imipenem 0 0 0 0 0 0 0 0 0 
Gentamicin 0.3 0 0 0 0 0.8 0 0 0 
Neomycin 1.2 0 0 0 0 3.3 3.1 0 0 
Tetracycline 53.6 72.7 61.5 33.3 90.7 51.2 68.8 45.2 90.0 
Sulphamethox. 48.8 67.5 69.2 44.4 92.2 50.4 31.3 45.2 65.0 
Trimethoprim 12.3 29.9 15.4 22.2 14.7 27.3 15.6 6.5 5.0 
Ciprofloxacin 0 0 0 0 0 0 0 0 0 
Nalidixic acid 3.9 1.3 0 0 5.4 2.5 3.1 3.2 0 
Chloramphenicol 28.4 32.5 38.5 22.2 85.3 3.3 12.5 29.0 5.0 
Florfenicol 28.1 31.2 38.5 22.2 85.3 3.3 9.4 29.0 5.0 
          
% fully sens 55% 37% 31% 40% 3% 32% 28% 48% 10% 
%R to 1 ant 10% 13% 8% 10% 7% 17% 41% 3% 20% 
%R to 2 ant 3% 4% 0% 0% 3% 5% 0% 3% 5% 
%R to 3 ant 9% 12% 15% 20% 1% 32% 13% 16% 60% 
%R to 4 ant 3% 4% 8% 0% 1% 9% 6% 0% 0% 
%R to >4 ant 21% 29% 38% 30% 85% 6% 13% 29% 5% 
DT104:  % 28% 35% 38% 22% - - - - - 
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Figure 11. Percentages of S. Typhimurium strains fully susceptible, resistant to one, two, three, four 
and more than four antibiotics in humans, pigs, cattle and poultry in The Netherlands in 2004.
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S. Paratyphi B var. Java 
S. Java is the predominant serovar isolated from broilers since 1998, however the proportion of of S. 
Java of all Salmonella’s that were sent in for typing in broilers decreased from 55.3% in 2003 to 
34.6% in 2004. At retail however (statistical sampling, table 15) no decrease is indicated. In 2004 
three strains with a resistance profile typical of the clone were isolated from Dutch human patients.  
From broilers and broiler products 33 strains were isolated, all harbouring the phenotype typical for 
the clone. Nalidixic acid resistance in S. Java isolated from poultry has remained stable in 2004 (Fig. 
13). No ciprofloxacin resistant strains were found. Resistance to amoxicillin and sulphamethoxazole 
shows a tendency to increase in 2004. Also cefotaxime resistance (ESBL-producers) shows a tendency 
to increase. Third-generation cephalosporins are not used in broilers, therefore the use of other beta-
lactam antibiotics or even other classes of antibiotics may select for beta-lactamases which are often 
located on integrons harbouring more resistance genes. 
 
 
 
 
 
 
 
Figure 13. Trends in resistance percentages of S. Paratyphi B var. Java isolated from poultry from 1999 – 
2004 and humans (blue bars indicate all humans isolates from 1999 – 2004 (N = 23))  
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Salmonella spp. in raw meat products of food-animals  
 
Table 14. Resistance % of Salmonella spp. isolated from raw meat from poultry, beef and pork products 
in 2004 
Poultry Beef Pork   
N = 112 N = 4 N = 7 
Amoxicillin 54.5 75 0 
Cefotaxime 10.7 0 0 
Imipenem 0 0 0 
Gentamicin 0 0 0 
Neomycin 0 0 0 
Doxycycline 10.7 50 28.6 
Trim/suplha 60.3 25 0 
Trimethoprim 72.3 25 0 
Sulphamethoxazole 45.5 - - 
Ciprofloxacin 0 0 0 
Nalidixic acid 37.5 0 0 
Chloramphenicol 1.8 25 0 
Florfenicol 1.8 0 0 
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Figure 14. Trends in resistance % of Salmonella spp. isolated from chicken products in the 
Netherlands from 2001 – 2004. 
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In general the resistance levels of Salmonella’s isolated from raw meat products are highest in poultry 
products compared to beef and pork, although the number of isolates tested from beef and pork are too 
small to draw firm conclusions (table 14). The observed resistance patterns and trends in the chicken 
isolates are strongly determined by the large contribution of S. Java (table 15). In beef and pork 
resistance is limited to older drug classes, while only in poultry products resistance to third-generation 
cefalosporins (cefotaxime), gentamicin and the quinolones occurs. Similar as observed in strains 
isolated from poultry faeces, an increase in amoxicillin and cefotaxime resistance was observed. 
Resistance trends are only presented for poultry products because in beef and pork the numbers of 
isolates examined are too small to provide an accurate estimate (Fig. 14).  
 
 
Table 15. Distribution of Salmonella serovars, in poultry meat at retail (Surveillance data of Food and 
Consumer Product Safety Authority (VWA-KvW)) 
 1997 1998 1999 2000 2001 2002 2003 2004 
sample size 1314 1077 859 1454 1578 1600 1510 1482 
Salmonella spp. positive (%) 29.1 20.2 17.6 21 16.3 13.4 11.3 7.4 
 Main serovars as a fraction of all isolates (%) 
Paratyphi B var. Java 15 11.4 13.9 33.1 43.2 53.5 45.6 58.2 
Enteritidis 20.2 12.8 26.4 6.6 8.2 2.3 8.8 5.5 
Hadar 10.1 6.1 4.5 3.3 4.2 0.9 1.8 - 
Indiana 6.1 8.3 9.3 10.2 11.6 6.5 6.4 1.8 
Infantis 9.2 5 3.6 6.6 7 7.9 11.7 - 
Virchow 4.6 2.8 2.6 10.2 3.5 5.6 5.8 4.5 
Typhimurium (DT104) 7.8 3.6(1.8) 1.3(0.7) 0.1(0.1) 7.4(7) 7.4(2.8) 5.8(5.3) 3.6 
Other  types  27 50 38.4 29.9 14.9 15.8 5.8 9.1 
 
 
Salmonella spp. in animal feeds, turkeys, horses, ducks, pigeon and reptiles 
In table 16 resistance data are presented for salmonella’s isolated from animal feeds and more 
incidental animal sources. A wide variety of serovars were isolated, S. Senftenberg, S. Agona, S. 
Mbandaka, S. Lexington were the most prevalent ones. The resistance percentages were much lower 
than those for the human and food-animal isolates and highest in S. Livingstone in different feed 
sources.  
In Salmonella’s isolated from turkeys, horses and ducks, more resistance was observed than in strains 
from pigeon or reptiles. Nalidixic acid resistance was highest in turkeys and ducks. 
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Table 16. The most prevalent serovars isolated from animals feeds and resistance percentages (R%) of 
isolates of Salmonella spp. per single and or compound feed type,  in 2001 - 2003 combined and 2004. 
Moreover R% of Salmonella strains isolated from incidental animal sources over 2001 – 2004 are 
presented. 
 
 Animal feed (or ground substance) Animals 
Serovars 
tested from feed, 
2001-2004 
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Senftenberg 139 Antibiotics % Resistant 2001-2004 R% 
R
% %-Resistant 2001-2004 
Agona  136 Amoxicillin 0 1 2 3 3 1 0.4 1 28 21 30 13 1 
Mbandaka  103 Cefotaxime 0 0 0 0 0 0 0 0 0 0 0 0 0 
Lexington  94 Imipenem 0 0 0 0 0 0 0 0 0 0 0 0 0 
Rissen  61 Gentamicin 0 0 0 0 0 0 0 0 4 0 0 0 0 
Anatum  59 Neomycin 0 0 0 0 0 0 0 0 12 0 0 0 0 
Livingstone 43 Tetracycline 0 1 14 4 10 8 0.7 5 28 24 10 13 3 
Tennessee  40 Sulfamethox 0 0 2 1 0 0 0.7 0 4 0 0 3 0 
Havana  39 Trimethoprim 0 1 3 1 1 2 0.7 1 4 21 0 0 0 
Cubana  38 Ciprofloxacin 0 0 0 0 0 0 0 0 0 0 0 0 0 
Kentucky  34 Nalidixic acid 0 1 0 0 2 2 0.2 1 20 3 20 0 0 
Oranienburg 31 Chloramph. 0 1 2 3 4 2 0.7 1 0 18 10 13 1 
Montevideo  25 Florfenicol 0 0 2 3 2 0 0.4 1 0 6 0 13 1 
13 main 
serovars 842(78%)               
All serovars 1079               
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Campylobacter spp. 
 
Highlights 
Highest resistance levels were observed in C. coli from pigs. Resistance to the quinolones was 
substantially higher in poultry, reflecting the use pattern of this antimicrobials class in these animals. 
Resistance to erythromycin was only present in C. coli and highest in strains from pigs.  
Also the prevalence of multiple resistant strains was highest in pigs compared to poultry. A tendency 
to increase in resistance can be observed in poultry for amoxicillin and doxycycline. Resistance to 
nalidixic acid and ciprofloxacin is stable. 
In domestically acquired human infections with C. jejuni up to 2% of the isolates were reported 
resistant to erythromycin. Because in C. jejuni strains isolated from Dutch poultry until 2005 not one 
erythromycin resistant strain has been detected, human infections with C. jejuni strains resistant to 
erythromycin are most likely travel related, caused by consumption of contaminated imported 
products or due to human therapy. 
 
Table 17. MIC distribution (in %) for all Campylobacter spp. isolated from broilers and slaughter pigs (N 
= 277) in The Netherlands in 2004 
MIC % distribution (µg/ml)  Campylobacter spp. 
2004 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 R% 
Amoxicillin  0.7 4.0 11.6 17.8 25.4 13.4 0.7 6.5 19.9     26.4 
Gentamicin  65.0 33.9 0.7 0.4          0 
Neomycin   24.9 67.5 4.3 0.7  1.4 0.7 0.4     2.5 
Streptomycin    23.1 10.1 3.6 0.4 5.1 37.5 10.8 2.5 7   62.8 
Doxycycline 13 6.9 2.9 1.1 1.8 6.5 23.1 31.0 13.7      67.9 
Trim/suplha  2.5 10.8 15.5 11.6 7.2 4.3 22.7 23.5 1.8     48 
Sulphamethoxazole       9.7 16.6 8.3 11.6 4 12.3 33.2 4.3 37.5 
Ciprofloxacin 43.3 31.8 6.9 0.7  0.4 3.2 8.3 5.4      17.3 
Nalidixic acid    1.4 14.8 35.4 28.5 2.2  1.1 12.3 4.3   17.7 
Erythromycin   2.5 2.9 16.6 32.5 32.1 5.4 0.7 0.7 6.5    13.4 
Metronidazole   7.2 28.9 13 6.1 6.5 10.1 14.1 9.4 4.7    44.8 
Chloramphenicol     19.9 46.2 28.2 5.4 0.4      0.4 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the breakpoints. 
 
Table 17 presents the MIC-distributions and resistance percentages for all campylobacters isolated 
from broilers and slaughter pigs in 2004. In table 10 these resistance percentages are presented 
separately for both animal and Campylobacter species and for both species isolated from poultry raw 
meat products. In Figure 15 the percentages of multiple resistance is presented for each animal and 
Campylobacter species, and the trends in resistance from 1999 – 2004 are presented in Figure 16.  
 
The MIC-distributions are bimodal for most antibiotics and although, internationally accepted 
interpretive criteria are lacking, for most antibiotics the breakpoints used distinguishes resistant from 
susceptible populations (table 17).  
Highest resistance percentages can be observed for streptomycin, doxycycline, metronidazole and 
(potentiated) sulphonamides. Resistance to the quinolones, erythromycin and amoxicillin are 
substantial. However differences in level of resistance exist both between C. jejuni and C. coli, and 
between pigs and broilers. Table 18 shows that except for amoxicillin, C. coli from poultry shows 
higher resistance levels than C. jejuni from poultry, as a result of the differences in species-specific 
capacity to become resistant. Moreover, resistance percentages for strains isolated from faeces or meat 
products are very similar. Highest resistance levels are observed in C. coli from pigs. Resistance to the 
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quinolones is substantially higher in poultry, reflecting the use pattern of this antimicrobials class in 
these animals. Resistance to erythromycin is only present in C. coli and highest in strains from pigs.  
In Campylobacter multiple resistance is highest in pigs compared to poultry. Resistance to three or 
more antibiotic classes in C. coli from pigs is present in 54% of the strains, in the same species from 
poultry in 38% of the strains and in C. jejuni in 40% of the strains (Fig. 15). 
A tendency to increase in resistance can be observed in poultry for amoxicillin and doxycycline. 
Resistance to nalidixic acid and ciprofloxacin is stable (Fig. 16). 
 
 
Table 18. Resistance percentages of C. jejuni and C. coli isolated from broilers and slaughter pigs in 2004 
 
 
Broilers 
C. jejuni 
(N = 57) 
Poultry  
products 
C. jejuni 
(N = 104) 
Broilers 
C. coli 
(N = 21) 
Poultry  
products 
C. coli 
(N = 55) 
Pigs 
C. coli
(N = 
199) 
Amoxicillin 50.0 22.1 4.8 16.4 22.2 
Gentamicin 0 0 0 1.8 0 
Neomycin 3.5 1.0 4.8 5.5 0 
Streptomycin 0 1.0 42.9 20.0 83.3 
Doxycycline 45.6 24.0 57.1 61.8 75.3 
Trim/suplha 7.0 4.8 33.3 18.2 61.6 
Sulphamethoxazole 5.3 4.8 28.6 16.4 48.0 
Ciprofloxacin 40.4 39.4 52.4 69.1 7.1 
Nalidixic acid 40.4 39.4 52.4 70.9 7.6 
Erythromycin 0 0 4.8 7.3 18.2 
Metronidazole 57.9 66.3 42.9 50.9 40.9 
Chlooramphenicol 1.8 0 0 0 0 
      
% fully Sensitive 19% 13% 5% 5% 5% 
% R to 1 antibiotic 18% 45% 24% 16% 15% 
% R to 2 antibiotics 23% 21% 33% 31% 26% 
% R to 3 antibiotics 26% 11% 19% 31% 25% 
% R to 4 antibiotics 7% 7% 14% 7% 16% 
% R to > 4 antibiotics 7% 3% 5% 9% 13% 
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Figure 15. Percentages of Campylobacter strains isolated from faecal samples fully susceptible, 
resistant to one, two, three, four and more than four antibiotics in  pigs and poultry in The 
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Figure 16. Trends in resistance percentages of C. coli isolated from slaughter pigs and broilers (grey striped bars),  
and C. jejuni  isolated from broilers from 1999 - 2004 
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Figure 17 shows that in human Campylobacter spp. resistance to fluoroquinolones (data are based on 
disk diffusion tests for norfloxacin, ofloxacin and ciprofloxacin) slowly increased in the last decade, 
but remained stable around 31% since 2000. In 2000 both resistance to fluoroquinolones and 
tetracyclines increased suddenly approximately 10%. A biological explanation for this phenomenon 
does not exist. Resistance to macrolides remained stable at a very low level.  
 
Disk diffusion is not advocated by CLSI for susceptibility testing of campylobacters and guidance on 
interpretive criteria is lacking, therefore these data have to be interpreted with care. 
 
 
Figure 17.  Trends in resistance % of Campylobacter spp. isolated from humans isolated between 1993 and 
2003 at the regional Public Health Laboratories (PHLs) of Arnhem and Heerlen covering 990.000 
inhabitants. The dotted line represent data from the national surveillance in 2002 - 2004; annually the 
average number of strains tested was approximately 2400, ranging from 1900 – 2900. 
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Table 19A. Domestically acquired and travel related resistance in C. jejuni and C. coli isolated from 
humans in 2004 from all 16 PHLs covering > 50% of the Dutch population and the resistance percentages 
in strains isolated by a general practitioner and a specialist. 
Domestically acquired Travel related All Campylobacter species 
C. jejuni C. coli C. jejuni C. coli Gen. Pract. Specialist 2004 data 
N R% N R% N R% N R% N R% N R% 
Fluoroquinolone 2092 32.6 97 33.0 188 54.3 14 64.3 2055 34.8 570 35.8 
Tetracycline 1499 18.9 85 18.8 118 21.2 13 15.4 1530 19.3 372 21.2 
Erythromycin 1816 1.7 90 2.2 163 1.2 14 -- 1811 1.6 487 2.1 
 
Table 19B. Effect of degree of urbanisation and rural source 
of human C. jejuni  isolates on resistance percentages 
 
C.  jejuni, not travel-related, 2004 isolates 
Degree of urbanisation Urban Rural 
Fluoroquinolone (N) 786 421 
R% 34.8 27.6 
Tetracycline (N) 598 277 
R% 23.2 13 
Erythromycin (N) 707 359 
R% 2.1 0.8 
 
 
Table 19A shows that in travel-related infections fluoroquinolone resistance occurred more frequently 
than in isolates from domestically acquired infections, for tetracycline and erythromycin this 
difference was not observed. No difference in resistance levels existed between campylobacters 
isolated in general practice compared to those after submission to a hospital (specialist).  
In domestically acquired strains of C. jejuni the resistance percentages are higher than in rural strains 
from areas (table 19B). This indicates that different sources of infection exist. 
 
In C. jejuni strains isolated from Dutch poultry until 2005 not one erythromycin resistant strain has 
been detected. Therefore human infections with C. jejuni strains resistant to erythromycin (table 19A 
and 19B) may be travel related or related to consumption of contaminated imported products, or due to 
human therapeutic use of macrolides.  
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Shigella toxin producing E. coli O157 
In 2004 78 strains of E. coli O157 were sent to RIVM for typing purposes or isolated from specimens 
taken from human faeces (37), veal calves and dairy cattle (41) in an attempt to trace a human clinical 
infection.  
 
Highlights 
The resistance levels for E. coli  O157 were low and were slightly higher in cattle isolates compared to 
those from human sources.  Resistance was limited to four older classes of antibiotics: amoxicillin, 
doxycycline, trimethoprim and sulphamethoxazole. Trends in resistance cannot be observed. 
 
 
Table 20. MIC distribution (in %) for E. coli O157 isolated in The Netherlands in 2004 from human (N = 
37) and cattle faeces (N = 41) 
MIC % distribution (µg/ml) 
Humans (37) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 
R% 
Amoxicillin         94.6     5.7    5.7 
Cefotaxim    97.3 2.7             0 
Imipenem    91.9 8.1             0 
Gentamicin     8.1 70.3 16.2 5.4          0 
Neomycin       89.2 8.1 2.7         0 
Doxycycline       2.7 91.9 2.7     2.7    2.7 
Sulphamethox          97.3       2.7 2.7 
Trimethoprim      97.3        2.7    2.7 
Ciprofloxacin   100               0 
Nalidixic acid        13.5 86.5         0 
Chloramphenicol          70.3 29.7       0 
Florfenicol         2.7 97.3        0 
MIC % distribution (µg/ml) 
Cattle (41) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 
R% 
Amoxicillin        2.4 90.2 2.4    4.9    4.9 
Cefotaxim    97.6  2.4            0 
Imipenem    90.2 7.3 2.4            0 
Gentamicin     19.5 70.7 4.9 4.9          0 
Neomycin       90.2 9.8          0 
Doxycycline        87.8 2.4     9.8    9.8 
Sulphamethox          90.2 2.4      7.3 7.3 
Trimethoprim      92.7 2.4       4.9    4.9 
Ciprofloxacin   92.7 7.3              0 
Nalidixic acid        19.5 75.6 2.4 2.4       0 
Chloramphenicol         2.4 78.0 19.5       0 
Florfenicol         12.2 85.4 2.4       0 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the breakpoint. 
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Figure 18.  Trends in resistance percentages of E. coli O157 isolated in The Netherlands from 1998 - 2004 
 
Resistance data from 1998 to 2004 demonstrate the absence of clear trends. Throughout the years the 
levels showed a lot of variation and only incidentally resistance to modern antibiotics like cefotaxime, 
gentamicin or nalidixic acid was observed.
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Food-borne commensal organisms 
The level of antimicrobial resistance in randomly sampled commensal organisms of the intestinal tract 
directly reflects the selection pressure as a result of the use of antibiotics as therapeutics or growth 
promoters in animals, especially over time. For this purpose, E. coli and Enterococcus faecium and E. 
faecalis, as indicator organisms for the Gram-negative and Gram-positive flora, are monitored. 
Isolation of bacteria from the intestine of randomly picked animals at slaughter aims to detect the 
development of resistance at the bacterial population level in food animals. Resistance percentages in 
tables 21, 23 and 24 indicate the level of resistance in all E. coli, E. faecium and E. faecalis strains of 
slaughter pigs and broilers, respectively. Because of the sampling strategy, this method is inherently 
insensitive for detecting resistance. If resistance is detected, even at low percentages, it indicates that 
the number of animals or groups of animals that carry these resistant bacteria is substantial 
Escherichia coli 
Highlights 
The resistance levels of E. coli show a tendency to increase in both pigs and broilers. Because 
commensal E. coli is present in all animals and the sample is taken randomly, the tendency of increase 
in resistance reflects the increased usage of antibiotics in these animals. The increased resistance is 
predominantly observed for the older antibiotics classes (amoxicillin, tetracycline, trimethoprim and 
sulphonamides). In broilers multiple resistance was substantially more commonly present than in pigs, 
which may reflect a higher selection pressure, but may also be due to the production system. Broilers 
only live approximately six weeks, therefore there is limited opportunity for reduction of resistance 
once selection took place. 
In broilers resistance to cefotaxime, indicative of extended spectrum beta-lactamases, was present at a 
high level. This is intriguing because third-generation cephalosporins are not used in poultry, therefore 
other selective determinants must exist. ESBLs are often located on integrons linked to other 
resistance genes. 
Resistance to nalidixic acid was highest in strains from poultry. The selection pressure as a result of 
treatment with quinolones is reflected in the higher resistance percentages in these animals. 
 
Both in slaughter pigs and broilers, the older classes of antibiotics, amoxicillin, doxycycline, 
trimethoprim, sulphamethoxazole and chloramphenicol showed the highest resistance levels (table 21). 
Moreover, the resistance levels in broilers were always higher than those in pigs. In broilers resistance 
to nalidixic acid was very high (46.3%). One nalidixic acid resistant strain was highly resistant to 
ciprofloxacin, al other nalidixic acid resistant strains showed reduced susceptibility to ciprofloxacin. 
Although the resistance levels for nalidixic acid from 1998 to 2004 show a certain annual variation, 
they show a tendency to increase (Fig. 20).  
 In broilers resistance to cefotaxime, indicative of extended spectrum beta-lactamases, was 
strikingly high (9.7%). Because the sample of 300 E. coli strains is randomly isolated from caecal 
samples at slaughter, it strongly indicates that the prevalence of ESBLs in broilers is substantial. This 
is intriguing because third-generation cephalosporins are not used in poultry, therefore other selective 
determinants must exist. ESBLs are often located on integrons linked to other resistance genes. These 
genes encode for resistance to a.o. amoxicillin, chloramphenicol, aminoglycosides, trimethoprim and 
sulphonamides. Except chloramphenicol, these antimicrobial classes are often used in broilers and 
therefore may co-select for ESBLs. In Enterobacteriaceae ESBLs are plasmid mediated. The E. coli 
strains may therefore be a source for transmission of ESBLs to animal-, or zoonotic human pathogens. 
The genetic nature of these ESBLs needs to be elucidated. 
 The resistance levels show a tendency to increase in both animal species in 2004 (Fig. 20). Figure 
19 shows that in broilers (73%) multiple resistance to three or more antibiotics was substantially 
higher than in pigs (41%). This may reflect difference in use patterns of antibiotics in these animals 
but may also be caused by the husbandry systems. Broiler fattening takes approximately six weeks, 
while pig fattening takes about six months. Therefore in pigs after selection of resistance before and 
during weaning, a reduction of resistance can occur during the months of fattening. In Sweden 
multiple resistance is much less common, the levels are 15% in pigs and 5% in chickens (SVARM 
2003 and 2004). 
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Table 21. MIC distributions (in %) for E. coli isolated from slaughter pigs (N = 296) and broilers (N = 
300) in The Netherlands in 2004. 
MIC % distributions (µg/ml) Pigs (296) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 
R%
Amoxicillin       2.0 14.5 37.5 19.9 0.7   25.3    25.3
Cefotaxime    98.6 0.7 0.3  0.3          0.3 
Imipenem    91.2 8.8             0 
Gentamicin     10.1 57.1 26.7 5.1 0.3 0.3   0.3     0.3 
Neomycin       64.5 26.0 7.4    1.0 0.7 0.3   2.0 
Doxycycline      0.7 7.8 24.7 2.0 1.0 1.7  12.2 49.7    63.7
Sulphamethox          47.0 0.3      52.7 52.7
Trimethoprim      47.3 9.1 0.3 0.3 0.3    42.6    42.6
Ciprofloxacin   96.6 2.0 0.3 0.7 0.3           0 
Nalidixic acid        42.2 54.7 1.4    0.7 1.0   1.7 
Chloramphenicol         3.4 77.7 6.8 2.7 5.1 2.4 2.0   12.2
Florfenicol        0.3 20.6 69.6 8.1 1.4      1.4 
MIC % distributions (µg/ml)   
Broilers (300) 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 R%
Amoxicillin        5.0 18.7 12.0 0.3   63.7    63.9
Cefotaxime    87.7 2.7   2.0 1.0 1.3 1.0 4.3      9.7 
Imipenem    88.0 11.7             0 
Gentamicin     2.7 62.7 24.7 4.7 0.3 0.7 2.3 1.3 0.7     4.3 
Neomycin       62.7 20.0 3.7 0.3 0.7 5.0 4.3 2.3 1.0   12.7
Doxycycline      0.3 5.7 21.7 5.7   0.3 19.7 46.7    66.7
Sulphamethox          27.3      0.3 72.3 72.7
Trimethoprim      30.0 7.3       62.7    62.7
Ciprofloxacin   54.7 4.3 26.3 10.7 3.3   0.3        0.3 
Nalidixic acid        26.3 26.0 1.3  1.0 1.3 14.7 29.3   46.3
Chloramphenicol         3.0 54.0 20.0 1.7 1.3 0.3 19.7   23.0
Florfenicol         12.7 75.0 10.3 1.0 0.7 0.3    2.0 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the breakpoints. 
 
 
Figure 19. Percentages of E. coli strains fully susceptible, resistant to one, two, three, four and more 
than four antibiotics in pigs and poultry in The Netherlands in 2004.
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Figure 20. Trends in resistance percentages of E. coli isolated from slaughter pigs and broilers in The Netherlands 
from 1998 - 2004 
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E. coli in raw meat products of food-animals 
 
Table 22. Resistance % of E. coli isolated from raw meat products of poultry, beef and pork in The 
Netherlands in 2004 
Poultry Bio-Chicken Beef Veal Pork Sheep 
  
N = 144 N = 41 N = 166 N = 27 N = 24 N = 26 
Amoxicillin 58.3 22 15.2 51.9 20.8 7.7 
Cefotaxime 2.1 0 1.5 3.7 0 0 
Imipenem 0 0 0 0 0 0 
Gentamicin 2.8 0 0 7.4 0 0 
Neomycin 7.6 0 7.6 22.2 0 0 
Tetracycline 47,9 31.7 27.3 74.1 41.7 11.5 
Trim/Sulpha 44.4 7.4 12.1 - 29.4 - 
Trimethoprim 46.5 12.2 12.1 44.4 20.8 3.8 
Ciprofloxacin 4.2 0 0 3.7 0 0 
Flumequine 22.2 4.9 1.5 25.9 0 0 
Chloramphenicol 9 2.4 4.5 37 8.3 3.8 
Florfenicol 0 0 0,0 14.8 0,0 0 
 
Resistance percentages of E. coli strains isolated from poultry products and pork (table 22) are very 
similar to those of isolates from broilers and pigs at slaughter (table 21, fig. 20), indicating that faecal 
contamination of poultry carcasses is an important factor in the transmission of E. coli. In E. coli from 
beef and sheep products, resistance percentages are lower to those in E. coli from pork; resistance in 
veal is at a substantially higher level.  
 
Resistance to flumequine was highest in strains from poultry products and veal, low in beef and not 
present in pork and sheep. Fluoroquinolones have been licensed for group treatment in broilers and 
veal calves since 1987 and flumequine since 1981. The selection pressure as a result of this type of 
treatment is reflected in the higher resistance percentages in these animals. 
 
Figure 21 shows trends in resistances in the different meat products. Although the resistance 
percentages show a general tendency to increase, these data have to be interpreted carefully. The 
observed tendency may be a normal variation due to sampling methods used and not reflect a true 
increase. 
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Figure 21. Trends in resistance percentages of E. coli isolated from raw meat products 
of poultry, cattle and pigs in The Netherlands from 2002 – 2004 and of sheep and veal 
calves in 2004.
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 Enterococcus faecium, Enterococcus faecalis 
In 2004 E. faecalis was included in the monitoring programme. From each sample taken at 
slaughterhouses inoculated on Slanetz and Bartley agar, after incubation at 42°C, both a colony typical 
for E. faecium and one typical for E. faecalis was selected. Further determination was done by PCR. 
The reason for the inclusion of E. faecalis was that after 1999, when most of the growth promoters 
were banned, a slow but constant decrease in isolation rate for E. faecium from faecal samples was 
observed. Because differences in intrinsic susceptibility exist between the two species for a.o. 
flavomycin and the streptogramins, the data will be reported separately. 
 
Highlights 
In 2004 E. faecalis was included in the monitoring programme. The reason was that the isolation rates 
of E. faecium decreased after 1999, the year of the partial ban of growth promoters. In slaughter pigs 
the resistance levels in E. faecium remained stable in 2004 as compared to 2003 (Fig. 13). In broilers 
resistance to doxycycline, erythromycin, streptomycin and salinomycin showed a slow tendency to 
increase.  
Multiple resistance to three or more antibiotics was commonly present and much more common in 
strains from broilers than in strains from pigs.  
Resistance percentages in E. faecium isolated from raw meat products were lower than those found in 
isolates from food-animals. This may be selection bias due to the relatively small numbers tested. It 
may also indicate that subpopulations of strains adapted to survival in meat products exist.  
Vancomycin resistance was only found in E. faecalis isolated from beef. Resistance levels in E. 
faecalis from veal were similar as those in poultry products. Resistance in biologically reared poultry, 
and sheep was lower than in other food animals. 
 
E. faecalis is intrinsically reduced susceptible to quinu/dalfopristin (table 23). The breakpoint R > 2 
µg/ml is not adequate for this species and should be > 32 µg/ml to distinguish the native from the 
resistant population. E. faecium is intrinsically high level resistant to flavomycin. The fact that the 
resistance levels for flavomycin presented in this chapter are not always 100% may be due to 
inadequate identification or genetic variations within the E. faecium population. 
Avilamycin was not included in the 2004 test panel because the producer refused to provide this active 
substance. The reason was that the broth microdilution method used is not validated for avilamycin. 
 
In E. faecalis and E. faecium strains isolated from broilers and pigs, next to doxycycline, the highest 
resistance percentages were found for those antibiotics representing the growth promoters: bacitracin,  
erythromycin representing tylosin and spriramycin, and quinu/dalfopristin (Synercid®) 
(streptogramins)  and salinomycin (ionophore) (tables 23 and 24). Resistance to the glycopeptide 
vancomycin was only detected in E. faecium from broilers (R = 1.1 %). Amoxicillin resistance was 
only detected in E. faecium and ciprofloxacin resistant strains were not detected. High-level 
streptomycin resistant strains were present in both animal and bacterial species.  
 
In pigs the resistance levels seemed to be stable, whereas in broilers the resistance levels show a 
tendency to increase (Fig. 22) .  Multi drug resistance is commonly present in strains from both animal 
species, but substantially more common in broilers than in pigs. In broilers 70% of E. faecalis and 
>90% of E. faecium was resistant to three or more antibiotic classes, while in pigs this was 55% and 
62%, respectively (Fig. 23).
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Table 23. MIC distributions (In %) for E. faecalis isolated from slaughter pigs (N = 35) and broilers 
(N = 110) in The Netherlands in 2004. 
MIC % distribution (µg/ml) 
Pigs N = 35 
0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
R (%)
Amoxicillin    100            0 
Bacitracin        2.9 5.7 34.3 34.3 5.7 17.1   22.9 
Chloramphenicol       74.3 17.1  8.6      8.6 
Ciprofloxacin   8.6 88.6 2.9           0 
Doxycycline  11.4 8.6   2.9 31.4 31.4 14.3       77.1 
Erythromycin    28.6 22.9     2.9  45.7    48.6 
Flavomycin      100          0 
Genta > 500           97.1   2.9  2.9 
Linezolid   2.9  94.3 2.9          0 
Salinomycin   8.6 65.7 11.4 2.9 11.4         11.4 
Strep > 2000             62.9 2.9 34.3 34.3 
Quinu/dalfopristn      2.9 17.1 77.1 2.9       100* 
Vancomycin    77.1 22.9           0 
MIC % distribution (µg/ml) 
Broilers N = 110 
0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
R (%)
Amoxicillin    99.1 0.9           0 
Bacitracin        0.9 10.0 7.3 41.8 7.3 32.7   40.0 
Chloramphenicol      5.5 80.9 9.1  4.5      4.5 
Ciprofloxacin   18.2 78.2 3.6           0 
Doxycycline  7.3 13.6 0.9  2.7 40.0 27.3 8.2       75.5 
Erythromycin    31.8 9.1 1.8 2.7 2.7 5.5 2.7  43.6    57.3 
Flavomycin      97.3 2.7         0 
Genta > 500           100     0 
Linezolid   0.9 3.6 95.5           0 
Salinomycin   4.5 42.7 7.3 10.9 34.5         34.5 
Strep > 2000             72.7 2.7 24.5 24.5 
Quinu/dalfopristin   1.8   0.9 25.5 67.3 3.6 0.9      98.2* 
Vancomycin    59.1 40.9           0 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the breakpoint. 
* E. faecalis is intrinsically decreased susceptible to streptogramins, therefore the R% data for quinu/dalfopristin 
(Synercid®) represent an overestimation of the resistant population. 
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Table 24. MIC distributions (In %) for E. faecium isolated from slaughter pigs (N = 121) and broilers (N = 
180) in The Netherlands in 2004. 
MIC % distribution  (µg/ml) Pigs  N =121 
 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
R (%) 
Amoxicillin       48.8 47.1 3.3 0.8                 0 
Bacitracin           19.0 7.4   1.7 2.5 22.3 21.5 25.6     47.1 
Chloramphenicol             91.7 7.4 0.8             0 
Ciprofloxacin     20.7 49.6 13.2 14.9 1.7                 0 
Doxycycline   22.3 1.7   0.8 0.8 7.4 38.8 27.3 0.8           74.4 
Erythromycin       15.7 42.1 9.9 5.8 1.7       24.8       32.2 
Flavomycin                         0.8 99.2   100* 
Genta > 500                     100.0         0 
Linezolid         79.3 19.8 0.8                 0.8 
Salinomycin       21.5 33.1 1.7 31.4 12.4               43.8 
Strep > 2000                         83.5 8.3 8.3 8.3 
Quinu/dalfopristin     5.8 5.8 35.5 44.6 8.3                 52.9 
Vancomycin     81.8 14.0 2.5 1.7                   0 
MIC % distribution  (µg/ml) Broilers  N = 180 
 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
R (%) 
Amoxicillin       42.2 37.2 15.6 0.6 0.6 2.2 1.7           4.5 
Bacitracin         0.6 1.1 3.9 6.7 1.7 0.6 7.8 20.6 57.2     77.8 
Chloramphenicol           2.8 74.4 13.9 8.9             0 
Ciprofloxacin     1.7 10.6 25.6 54.4 7.8                 0 
Doxycycline   21.7 0.6 0.6 2.8 1.1 23.3 17.2 32.8             73.3 
Erythromycin       18.3 8.3 3.9 1.1   0.6 0.6 0.6 66.7       69.4 
Flavomycin                       0.6 7.2 92.2   100* 
Genta > 500                     96.1 1.1 0.6 2.2   2.2 
Linezolid       1.7 87.8 10.6                   0 
Salinomycin       6.1 8.3 3.9 78.9 2.8               81.7 
Strep > 2000                         66.1 1.7 32.2 32.2 
Quinu/dalfopristin     6.7 12.8 10.6 48.3 8.9 8.3 4.4             70.0 
Vancomycin     73.3 16.7 8.3 0.6       0.6 0.6         1.1 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the breakpoint. 
* Intrinsic resistance to flavomycin. 
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Figure 22. Trends in resistance percentages of E. faecium isolated from slaughter pigs and broilers in The 
Netherlands from 1998 - 2004 
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Figure 23. Percentages of E. faecalis and E. faecium strains fully susceptible, resistant to one, two, 
three, four and more than four antibiotics in pigs and poultry in The Netherlands in 2004. 
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E. faecium and E. faecalis in raw meat products of food-animals 
Table 25. Resistance % of E. faecalis and E. faecium isolated from raw meat products from poultry, bio-
chickens, beef, veal, sheep and pork in the Netherlands in 2004 
Poultry Bio-chicken Beef Veal Sheep Pork E. faecalis 
N = 24 N = 17 N = 130 N = 37 N = 25 N = 61 
Amoxicillin 0 0 0 0 0 0 
Bacitracin 33.3 35.3 9.9 35.1 40 4.9 
Ciprofloxacin 0 0 1.4 0 0 3.3 
Doxycycline 62.5 29.4 22.2 45.9 28 20 
Erythromycin 41.7 14.3 12.5 32.4 8 1.6 
Flavomycin 8.3 0 5.6 8.1 4 1.6 
Gentamicin > 500 µg/ml 4.2 0 2.8 5.4 0 0 
Linezolid - - - 0 0 - 
Salinomycin 0 - 0 0 0 0 
Streptomycin > 1000 µg/ml 12.5 - 10.8 - - 0 
Streptomycin > 2000 µg/ml 8.3 0 7 17.1 0 0 
Quinu/dalfopristin 100* 100* 86.1* 89.2* 56.0* 82.0* 
Vancomycin 0 0 1.4 0 0 0 
Poultry Bio-chicken Beef Veal Sheep Pork 
E. faecium 
N = 42 N = 20 N = 46 N = 12 N = 20 N = 17 
Amoxicillin 4.8 0 0 0 0 0 
Bacitracin 61 15 17.4 0 5 5.9 
Ciprofloxacin 0 10 0 0 - 0 
Doxycycline 57.1 20 17.4 8.3 10 29.4 
Erythromycin 57.1 5 10.9 25 5 17.6 
Flavomycin 73.2* 60* 100* 100* 85* 82.4* 
Gentamicin > 500 µg/ml 0 15 0 0 0 0 
Linezolid - - - 0 0 - 
Salinomycin 9.8 0 4.3 0 0 11.8 
Streptomycin > 1000 µg/ml 24.4 0 4.3 - - 0 
Streptomycin > 2000 µg/ml 9.8 - 2.2 0 5.6 0 
Quinu/dalfopristin 19.0 11.1 0 0 5 5.9 
Vancomycin 0 0 0 0 0 0 
* E. faecalis is intrinsically decreased susceptible to streptogramins, therefore the R% data for quinu/dalfopristin 
(Synercid®) represent an overestimation of the resistant population. E. faecium is intrinsically resistant to 
flavomycin. 
 
Resistance percentages in E. faecium isolated from raw meat products are lower than those found in 
isolates from food-animals. This may be selection bias due to the relatively small numbers tested. It 
may also indicate that subpopulations of strains adapted to survival in meat products exist.  
 
Vancomycin resistance was only found in E. faecalis isolated from beef. Resistance percentages in 
isolates from beef were lower than those from the poultry and pig products. Resistance levels in E. 
faecalis from veal were similar as those in poultry products.  
Resistance levels in E. faecalis were similar to those from E. faecium except for bacitracin and 
doxycycline from cattle.  
Resistance in biologically reared poultry was in general lower than in broilers. Surprisingly two E. 
faecium strains from bio-chickens showed high level resistance to ciprofloxacin. 
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Fig 16 shows the trend from 2002 to 2004. Real trends cannot be observed and trend analysis is 
complicated by the relatively small numbers of strains per year. 
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Figure 24. Trends in resistance percentages in E. faecalis and E. faecium isolated from raw meat products 
from poultry, beef and pork in The Netherlands from 2002 to 2004
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Listeria monocytogenes 
All strains isolated from 2001 to 2004 and sent to the National Institute of Public Health and the 
Environment (RIVM), Bilthoven for confirmation and typing (N = 146) were tested for susceptibility 
using broth microdilution. The origin of the strains was predominantly human; 55% were isolated 
from blood samples and 25% from liquor. The remaining 20% was isolated from environmental 
specimens and various food products. 
The purpose of this study was to determine the susceptibility level of Listeria spp. to a wide variety of 
antimicrobial agents used in human and veterinary medicine. 
The strains were tested for susceptibility to amoxicillin, neomycin, gentamicin, tetracycline, 
doxycycline, erythromycin, ciprofloxacin, chloramphenicol, florfenicol, imipenem, 
sulphamethoxazole, trimethoprim, linezolid, salinomycin, quinu/dalfopristin and vancomycin. 
 
Highlights 
The strains were all susceptible to all antibiotics listed, except 6 that were resistant to 
sulphamethoxazole (MIC > 1024 µg/ml).  
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Animal pathogens 
Bovine mastitis pathogens E. coli, coliform bacteria, S. aureus, coagulase-negative 
staphylococci, S. uberis and S. dysgalactiae. 
 
Highlights 
In general E. coli strains isolated from milk samples from cows suffering from mastitis were 
susceptible to the antibiotics included in the panel. The coliform bacteria (Enterobacter, Klebsiella 
and other species) showed a high level of resistance to amoxicillin, and to the combination with 
clavulanic acid. The S. aureus isolates tested were susceptible to most antibiotics, 12.1% were 
penicillin resistant. Oxacillin resistance (MRSA) was not present. The coagulase negative 
staphylococci were more resistant than S. aureus, 40.8% were resistant to penicillin and 6.1% to 
oxacillin (mecA-positive). In the streptococci only resistance to erythromycin, lincomycin, pirlimycin 
and tetracycline was observed. In 2004 S. uberis was more frequently resistant to erythromycin, 
lincomycin and pirlimycin than S. dysgalactiae. Resistance to tetracycline was highest in S. 
dysgalactiae.  
 
Table 26. MIC-distributions (in %) for E. coli and coliform bacteria isolated from mastitis milk samples 
from Dutch cattle by the Animal Health Service in Deventer in 2004. 
MIC % distribution (µg/ml) E. coli (N = 101) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
R%
Amoxicillin       2.0 19.8 52.5 10.9 1.0  13.9   13.9
Amox-clavulanic acid       3.0 32.7 45.5 15.8 3.0     0 
Cefquinome   92.1 7.9            0 
Cefoperazone   5.9 35.6 33.7 9.9 4.0 6.9 3.0 1.0      0 
Cefuroxime        13.9 50.5 34.7 1.0     0 
Tetracycline       35.6 45.5 4.0    14.9   14.9
Gentamicin     5.0 57.4 30.7 6.9        0 
Kanamycin        16.8 58.4 18.8  5.9    5.9 
Neomycin      3.0 68.3 18.8 4.0  1.0 5.0    5.0 
Streptomycin         14.9 63.4 5.9  5.9 9.9  15.8
Enrofloxacin  70.3 28.7       1.0      1.0 
Trim/Sulphamethoxazole    85.1 4.0 2.0      8.9    8.9 
MIC % distribution (µg/ml) 
Coliform (N = 88) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
R%
Amoxicillin        9.1 6.8 1.1 1.1 1.1 80.7   81.8
Amox-clavulanic acid       6.8 54.5 9.1 2.3 1.1 1.1 22.7 2.3  26.1
Cefquinome   75.0 17.0 6.8 1.1          0 
Cefoperazone   1.1 10.2 31.8 19.3 10.2 14.8 9.1 3.4      0 
Cefuroxime       4.5 34.1 28.4 10.2 6.8 15.9    15.9
Tetracycline      3.4 26.1 45.5 10.2 1.1 1.1 3.4 9.1   13.6
Gentamicin    1.1 38.6 52.3 8.0         0 
Kanamycin       6.8 53.4 25.0 4.5 1.1 9.1    9.1 
Neomycin     2.3 28.4 59.1 5.7 3.4 1.1      0 
Streptomycin        5.7 63.6 19.3 1.1 2.3 3.4 4.5  7.9 
Enrofloxacin  31.8 52.3 10.2 4.5 1.1          0 
Trim/Sulphamethoxazole    64.8 28.4 3.4 2.3     1.1    1.1 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
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E. coli strains isolated from milk samples from cows suffering from mastitis were in general 
susceptible to the antibiotics included in the panel. Only resistance to amoxicillin, streptomycin, 
trim/sulpha and tetracycline was present in significant percentages. All strains were susceptible to the 
2nd (cefuroxime) and 3rd generation cefalosporins (cefquinome and cefoperazone) tested, although the 
cefoperazone MICs show a wide variation in the level of the susceptibilities. One isolate was resistant 
to enrofloxacin. In comparison with the commensal E. coli’s from food animals often showing 
subpopulations with decreased susceptibility to fluoroquinolones, the one resistant isolate was high-
level resistant to fluoroquinolones. All isolates were susceptible to gentamicin.  
 
The coliform bacteria (29 Enterobacter , 48 Klebsiella, 11 other species) showed a high level of 
resistance to amoxicillin (almost all klebsiella’s are ß-lactamase producers), and to the combination 
with clavulanic acid (predominantly Enterobacter and other species). The coliform bacteria produced 
beta-lactamases that were in 15.9% of the cases resistant to the second-generation cephalosporin 
cefuroxime but were always susceptible to the third-generation cephalosporins. Fig. 25 shows that 
from 2002 to 2004 the resistance levels are stable. 
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Figure 25.  Trends in resistance percentages for E. coli and coliform bacteria isolated from  clinical 
mastitis cases in dairy cattle in the Netherlands from 2002 – 2004.
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Table 27. MIC-distributions (in %) of S. aureus and coagulase-negative staphylococci isolated from 
clinical mastitis cases in dairy cattle by the Animal Health Service in Deventer in 2004. 
MIC % distributions (µg/ml) S. areus (N = 99) 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512
R%
Penicillin   85.9 2.0   2.0 1.0 4.0 3.0 2.0      12.1
Oxacillin    26.3 35.4 35.4 3.0          0 
Amox-clavulanic acid    58.6 28.3 4.0 9.1          0 
Cephalothin    26.3 45.5 24.2 3.0 1.0         0 
Tetracycline     7.1 89.9 1.0   1.0 1.0      1.0 
Kanamycin      1.0 3.0 48.5 43.4 4.0       0 
Neomycin    1.0 13.1 62.6 22.2 1.0         0 
Streptomycin         24.2 60.6 13.1   2.0   2.0 
Erythromycin     68.7 30.3 1.0          0 
Lincomycin      3.0 90.9 1.0   1.0 2.0 2.0    5.1 
Pirlimycin     18.2 63.6 15.2  3.0        3.0 
Trim/sulpha    96.0 3.0 1.0           0 
MIC % distributions (µg/ml) Coagulase neg.  
Staphylococci  
(N = 98) 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512
R%
Penicillin   52.0 7.1 11.2  3.1 9.2 6.1 4.1 7.1      40.8
Oxacillin   2.0 19.4 42.9 23.5 6.1 3.1 1.0 1.0 1.0      6.1*
Amox-clavulanic acid    44.9 33.7 15.3 5.1 1.0         0 
Cephalothin   2.0 18.4 51.0 21.4 6.1 1.0         0 
Tetracycline    3.1 36.7 35.7 2.0 2.0 3.1 1.0 2.0 14.3     16.3
Kanamycin    1.0 18.4 30.6 29.6 13.3 6.1   1.0     1.0 
Neomycin    77.6 16.3 3.1 2.0  1.0        0 
Streptomycin      3.1 13.3 30.6 25.5 12.2 4.1 4.1 4.1 3.1   11.3
Erythromycin    6.1 46.9 40.8 1.0  1.0 1.0 1.0 2.0     4.1 
Lincomycin     4.1 29.6 38.8 8.2 5.1 3.1 2.0 2.0 7.1    14.3
Pirlimycin    18.4 51.0 19.4 3.1 3.1 3.1   2.0     5.1 
Trim/sulpha    43.3 43.3 13.4           0 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
* all strains with MIC ≥ 2 µg/ml (6.1%) were mecA-positive 
 
In spite of the intensive use of antibiotics in the control of bovine mastitis in The Netherlands, the S. 
aureus isolates tested were susceptible to most antibiotics. In 2004 12.1% of the isolates were 
penicillinase producers but oxacillin resistance was not present, 5.1% were resistant to lincomycin and 
3% to the related but more potent lincosamide drug, pirlimycin.  
 
The coagulase negative staphylococci were more resistant than S. aureus. In 2004, 40.8% were 
resistant to penicillin and 35.7% to oxacillin using the breakpoint 0.25 µg/ml. CLSI standard M31-A2 
prescribes for oxacilline as breakpoint R ≥ 4 µg/ml. A study done in the EU-project ARBAO-II, 
coordinated by the Danish Institute for Food and Veterinary Research demonstrated that using the R 
breakpoint ≥ 4 µg/ml would lead to an underestimation of mecA (the gene encoding for oxa/methicillin 
resistance) positive strains. However, using the breakpoint prescribed in CLSI standard M100-S15 
intended for human medicine for coagulase negative staphylococci, R ≥ 0.5 µg/ml lead to an 
overestimation of mecA-positive strains. Therefore it was suggested that all strains with oxacillin 
MICs ≥ 4 µg/ml and those with MICs ≥ 0.5 µg/ml but PCR confirmed mecA-positive should be 
classified resistant. Using this method the resistance percentage for oxacillin was 6.1%; six strains 
were mecA-positive, their oxacilline MICs varied from 2 - > 8 µg/ml.  
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Resistance to tetracycline (16.3%), lincomycin (14.3%) and streptomycin (11.3%) was quite 
commonly present. Resistance to pirlimycin was substantially lower (5,1%). 
Although the numbers of strains included were relative large, the trends in resistance in fig. 26 may be 
affected by selection bias and not reflect true trends.
Figure 26.  Trends in resistance percentages for S. aureus and coagulase negative staphylococci isolated from 
mastitis milk in The Netherlands from 2002 - 2004.
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Table 28. MIC-distributions (in %) of S. uberis and S. dysgalactiae isolated from mastitis milk samples 
from Dutch cattle by the Animal Health Service in 2004. 
MIC % distribution (µg/ml) 
S. uberis (N = 99) 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 R%
Penicillin 49.5 5.1 12.1 20.2 11.1 1.0 1.0            0 
Amox/clav. Acid 13.1 35.4 7.1 20.2 23.2   1.0           0 
Cephalothin    41.4 14.1 31.3 13.1            0 
Erythromycin   53.5 31.3   5.1  2.0    8.1     15.2
Lincomycin    22.2 10.1  1.0 22.2 9.1  1.0 3.0 31.3     35.4
Pirlimycin  2.0 46.5 14.1 1.0 2.0 1.0 9.1 16.2 1.0 2.0 2.0 3.0     24.2
Trim/sulpha    1.0 24.2 58.6 15.2  1.0           0 
Tetracycline     0.0 2.0 20.2 36.4 5.1 1.0    20.2 13.1 2.0   35.4
MIC % distribution (µg/ml) S. dysgalactiae 
 (N = 90) 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 R%
Penicillin 97.8 1.1 1.1                0 
Amox/clav. Acid 94.4 4.4 1.1                0 
Cephalothin   20.0 76.7 3.3              0 
Erythromycin 1.1 10.0 78.9 3.3         6.7     6.7 
Lincomycin    37.8 35.6 1.1  1.1 3.3 7.8  1.1 12.2     21.1
Pirlimycin 1.1 18.9 50.0 16.7  1.1   2.2 2.2 1.1 1.1 5.6     12.2
Trim/sulpha   1.1 7.8 66.7 21.1 3.3             0 
Tetracycline        1.1 1.1 11.1 18.9 1.1 1.1 10.0 55.6    67.8
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
 
In 2004 S. uberis was more frequently resistant to erythromycin, lincomycin and pirlimycin than S. 
dysgalactiae. Resistance to tetracycline was highest in S. dysgalactiae.  
The observed differences in resistance percentages of the lincosamides and trimethoprim-
sulphamethoxazole for S. uberis between 2002 and 2004 are striking (fig. 20), but again it may be part 
of the normal variation and not represent a real trend.  
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Figure 27.  Trends in resistance percentages for S. uberis and S. dysgalactiae isolated from mastitis milk in The 
Netherlands from 2002 - 2004. 
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Enteric pathogens: Brachyspira hyodysenteriae 
 
Highlights 
Of the strains tested 68.8% was resistant to tylosin and 0% resistant to tiamulin 
 
Table 29. MIC % distribution for B. hyodysenteriae isolated from pigs in the Netherlands in 2003 - 2004 
MIC % distribution (µg/ml) N = 16 
0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 32 64 128 256 
R% 
Tylosin        25 6.2     68.8 68.8 
Tiamulin  68.8 31.3            0 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
 
 
In 2002 CIDC-Lelystad started with the monitoring of resistance to tylosin and tiamulin in B. 
hyodysenteriae in The Netherlands. The inclusion of this bacterial species in the programme was 
considered important because of the realistic scenario that this species is becoming resistant to all 
drugs licensed. Tylosin and tiamulin are included, because they represent all antibiotics used to treat 
dysentery in pigs. Tylosin is cross resistant with lincomycin and tiamulin with valnemulin. The strains 
tested are all isolated from animals suffering from swine dysentery at the Animal Health Service in 
Deventer, The Netherlands. In 2002 all isolates tested were resistant to tylosin, therefore it was 
surprising to find 5 tylosin (lincomycin) susceptible isolates of B. hydoysenteriae in the small 
collection of strains isolated in 2003/2004. All isolates were susceptible to tiamulin (and therefore also 
to valnemulin). 
 
Poultry pathogen Mycoplasma synoviae 
In 2004 a selection of M. synoviae strains isolated from specimens taken from diseased poultry in the 
Netherlands were quantitatively tested for susceptibility to a number of antibiotics available in 
veterinary medicine. The direct reason was that M. synoviae infections in poultry poorly responded to 
antibacterial therapy and little knowledge existed on the susceptibility of clinical isolates. 
Mycoplasma’s are by nature fastidious organisms and routinely not tested for susceptibility. Moreover 
validated and well-standardised methodologies are lacking. To test the susceptibility a method adopted 
from the one described by P.C. Hannan in Veterinary Research in 2000 was used (see appendix. 
Materials and Methods).  
 
Highlights 
All strains were susceptible to doxycycline and the macrolides: tylosin and tilmicosin. Resistant 
subpopulations existed for the fluoroquinolones. For enrofloxacin the subpopulation with MICs 
varying from 4 - 16 µg/ml were more clearly separated from the susceptible population than for the 
related compound difloxacin.  
Table 30. MIC % distribution for M. synoviae isolated from poultry in the Netherlands in 2003 - 2004 
MIC % distribution M. synoviae  
(N = 17) 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 
R% 
Doxycycline - 11.8 35.3 47.1 5.9 - - - - - - - 0 
Tylosin 52.9 29.4 5.9 - 5.9 5.9 - - - - - - 0 
Tilmicosin - - - 35.3 47.1 17.6 - - - - - - 0 
Enrofloxacin - - - 5.9 23.5 29.4 17.6 - 5.9 11.8 5.9 - 23.5 
Difloxacin - - - - 5.9 29.4 41.2 11.8 11.8 - - - 11.8 
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III  Appendices 
Appendix I.  Materials and Methods 
Salmonella spp. 
A total of 10.234 isolates were tested for antimicrobial resistance between 1999-2004 (table 31). 
Human isolates (N=5618) concerned a selection from first isolates sent to the Dutch National Institute 
of Public Health (RIVM) by the regional public health laboratories. All strains were the first isolates 
recovered from patients with salmonellosis. The majority of the isolates from pigs (N=754) and cattle, 
including calves (N=265) were sent to the RIVM by the Animal Health Service concerning 
approximately 80% clinical Salmonella infections. Those from chickens (broilers, including poultry 
products, N=872; layers, reproduction animals and eggs, N=512) concerned mainly nonclinical 
Salmonella infections derived from a diversity of monitoring programs on the farm, slaughterhouses 
and at retail. In 2001, 2002, 2003 and 2004 isolates from a diversity of other sources have been 
analysed as well (animal fodder and human food products; other animals from animal husbandry and 
pets, samples from the environment, etc.). 
 
Table 31. Number of Salmonella isolates tested for susceptibility from 1999 – 2004 in the Netherlands. 
 Total 1999 2000 2001 2002 2003 2004 
Human 5618 674 349 1056 862 1338 1339 
Pig 754 31 195 114 168 127 119 
Cattle 265 18 28 56 33 24 106 
Chicken (misc.) 517 0 20 154 142 172 29 
Broilers (faeces/meat) 872 68 100 164 238 192 110 
Layers/Repro/Eggs 512 93 86 80 69 91 93 
Other sources 1696 22 22 331 353 486 482 
Total 10234 906 800 1955 1865 2430 2278 
 
 
 
Representativeness of percentages of resistance for humans or animals over all types 
In principal, if isolates are selected randomly from a source the percentage of resistant strains within a 
source can be computed straightforwardly. Standard statistical considerations would apply to indicate 
significant differences between years and between animal and human sources. Table 32 shows that 
quite substantial numbers are needed to indicate significant differences in resistance percentages less 
than 10%. However, resistance strongly depends on Salmonella type and many different types are 
involved; a cocktail of types that differs between sources and that may differ between years. 
Moreover, low numbers tested and incidentally missed, or selected types with rare antibiograms, may 
influence the resulting resistance percentages. Finally the source definition in itself may be biased, as 
the reason for sending-in isolates, especially from cattle and pigs, is often unknown. This explains 
many of the irregularities between years. 
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Table 32. Power analysis to show the sample sizes needed to indicate significant differences in resistance 
percentages between groups (for example between years or between human and animal sources). 
Level of significance = 0,05 and Power = 0,7 
R-group 1 R-group 2 Difference N1=N2 
40% 30% 10% 287 
30% 20% 10% 251 
20% 10% 10% 211 
70% 50% 20% 111 
60% 40% 20% 95 
50% 30% 20% 84 
40% 20% 20% 70 
30% 10% 20% 59 
60% 30% 30% 23 
 
 
 
E. coli, E. faecium, E. faecalis and Campylobacter spp. isolated from slaughter 
pigs and broilers 
E. coli and E. faecium, E. faecalis and Campylobacter spp. were isolated from faecal samples taken 
from healthy animals at slaughter by the National Inspection Service for Livestock and Meat (RVV). 
Six pig- and six broiler slaughterhouses respectively, were randomly selected. These slaughterhouses 
were situated all over the country to eliminate potential regional differences. The sampling period in 
2004 was January - April. At each slaughterhouse once daily from one animal a faecal sample (pigs) 
was taken aseptically, or the caeca collected (broilers). The vials were stored at 4 – 8°C until the next 
Monday, when they were sent to CIDC-Lelystad. At the Department of Bacteriology and TSEs the 
samples were directly 1:10 diluted in buffered peptone solution with 20% glycerol and stored at –
20°C. E. coli, E. faecium, E. faecalis and Campylobacter spp. were isolated directly after arrival of the 
samples at CIDC-Lelystad. For E. coli MacConkey agar and for the enterococci Slanetz and Bartley 
agar was inoculated with 50 µl of serial dilutions of the sample in saline with a spiral plater 
(enterococci) or direct inoculation of the plates with cotton swabs (E. coli). A colony with typical 
morphology was subcultured to obtain a pure culture and stored at –80°C in buffered peptone water 
with 20% glycerol. E. coli was identified biochemically. The final identification of the enterococci was 
done with Polymerase Chain Reaction (PCR) as described by Dutka Malen in 1995.  
For isolation of Campylobacter CCDA-agar with 32 µg/ml cefoperazone and 10 µg/ml amphotericin B 
to inhibit growth of Gram-negative bacteria and fungi, was directly inoculated with a cotton swab. All 
campylobacters were typed with PCR to the species level. Only C. jejuni and C. coli were tested for 
their susceptibility. All other spp. were excluded from the programme. 
E. coli, E. faecium and E. faecalis isolated from raw meat products of food-
animals 
For isolation of all bacterial species raw meat products were rinsed with Buffered Peptone Water 
(BPW). For E. coli 10 ml BPW rinse was enriched in 90 MacConkey-, or Laurylsulphate broth. After 
overnight aerobic incubation at 44°C the broth was subcultured on Coli-ID agar (24 h at 44°C). For 
enterococci 10 ml BPW rinse was enriched in 90 ml Azide Dextrose broth. After overnight aerobic 
incubation at 44°C, the broth was subcultured on Slanetz and Bartley agar for 48 hrs at 44°C. 
Identification was done biochemically. 
 
Shigella toxin producing E. coli O157 (STEC) 
For STEC both human and animal strains were combined. All sorbitol negative human strains from all 
medical microbiological laboratories in the Netherlands were sent to RIVM for serovar O157 
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confirmation and further typing. The animal strains were partly isolated in the monitoring programme 
of farm-animals of VWA-KVW/RIVM. These samples were taken at farms from faeces of healthy 
animals. One isolate per farm was included. Isolates from non-human sources included strains isolated 
from samples taken in an attempt to trace a human infection. 
 
Bovine mastitis pathogens E. coli, coliform bacteria, S. aureus, coagulase-negative 
staphylococci, S. uberis and S. dysgalactiae. 
Annually at the Animal Health Service large numbers of milk samples from clinical cases of bovine 
mastitis are sent in for bacteriological examination. From the isolates a selection of approximately 100 
strains of E. coli, coliform bacteria, S. aureus, coagulase-negative staphylococci, S. uberis and S. 
dysgalactiae were sent to CIDC-Lelystad for MIC-determinations. Inclusion criteria for the strains 
were: a maximum of one isolate per species per farm, only pure cultures were included after direct 
inoculations from the milk samples on agar plates, except for S. aureus for which species also pure 
cultures after broth enrichment were included. 
Brachyspira hyodysenteriae 
Strains isolates by the Animal Health Service in Deventer from intestines of diseased animals and 
identified as B. hyodysenteriae were sent to CIDC Lelystad for susceptibility testing. 
Mycoplasma synoviae 
Mycoplasme strains isolated from diseased poultry were sent by the Animal Health Service in 
Deventer to CIDC Lelystad for susceptibility testing. The species identification was confirmed by 
PCR. 
Susceptibility tests 
Susceptibility was tested quantitatively with the broth micro dilution test with cation-adjusted Mueller 
Hinton broth according to NCCLS guidelines (M31-A2 and M7-A6). For broth micro dilution, 
microtitre trays were used with dehydrated dilution ranges of custom made panels of antibiotics. Trek 
Diagnostic Systems, in the UK, manufactured these microtitre trays. For the Campylobacter spp., after 
inoculation of the microtitre trays with 50 µl of a 200 fold diluted 0.5 McFarland suspensions in saline 
solution, the trays were incubated micro aerobically in a shaking incubator at 37°C for 48 hours. 
ATCC strains E. coli 25922 and E. faecalis 29212 were used daily to monitor the quality of the results. 
For quality control of the results of campylobacters, C. jejuni ATCC 33560 was used as control strain.  
The MICs were defined as the lowest concentration without visible growth. Strains with MIC’s higher 
than the MIC-breakpoints were considered resistant. Percentages of resistance were calculated. These 
were based on MIC-breakpoints listed in table 34. 
B. hyodysenteriae was tested by broth dilution as described by Märit Pringle et al. in 2002. 
Mycoplasma’s are by nature fastidious organisms and routinely not tested for susceptibility. Moreover 
validated and well standardised methodologies are lacking. To test the M. synovia strains for 
susceptibility a method adopted from the one described by P.C. Hannan in Veterinary Research in 
2000 was used. As growth media ME-liquid medium (Mycoplasma experience Ltd) was used for the 
broth micro dilution test and as solid medium M.E. solid medium for avian mycoplasma’s was used 
produced by the same company. 
To determine the concentration of the inocula, for each strain serial dilutions of pure cultures were 
inoculated in ME-broth. Subsequently, for all five antibiotics used twofold dilutions concentration 
ranges varying from 0.03 – 64 µg/ml were prepared in microtitre trays I ME-broth and stored at -80°C 
pending analysis. To validate the concentration ranges of the antibiotics made and the potential effect 
of the broth and the incubation conditions (5% CO2, 37°C), ATCC control strains E. coli 25922 and S. 
aureus 29213 were inoculated in the test plates used. The results for the control strains (table 33) 
demonstrate that the results always complied with CLSI criteria and that the growth medium and 
incubation conditions have had no effect on the activity of the antibiotics in the microtitre trays. 
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Table 33. Results of QC-strains tested for susceptibility in the microtitre trays used for Mycoplasma 
synoviae. 
Control strain Antibiotic MIC CIDC (µg/ml) CLSI range (µg/ml) 
E. coli ATCC 25922 Enrofloxacin 
Difloxacin 
Doxycycline 
Tylosin 
Tilmicosin 
0.015 – 0.03 
0.06 – 0.125 
1 
> 32 
> 32 
0.008 – 0.003 
0.015 – 0.125 
0.5 – 2* 
> 32 
≥ 64 
S. aureus ATCC 29213 Enrofloxacin 
Difloxacin 
Doxycycline 
Tylosin 
Tilmicosin 
0.125 
0.25 
0.125 
1 
2 
0.03 – 0.125 
0.06 – 0.5 
0.125 – 0.5* 
0.5 – 4 
1 - 4 
 Antibiotic MIC CIDC (µg/ml) MIC Hannan et al. 2000 
(µg/ml) 
M. synoviae ATCC 
25204 
Doxycycline 
Enrofloxacin 
Tylosin 
0.125 
0.5 
≤ 0.015 
0.1# 
0.5 
0.01 
* CLSI control range 
# Hannan determined tetracycline MICs 
 
The microtitre trays were inoculated with 50 µl of 104 Colour Changing Units/ml in each 
well. The plates were visually controlled for colour changes from red to yellow on days 1, 2, 
3, 4, 7, 8, 9 and 14. From day 7 no further change in MIC was recorded, therefore the MIC 
recorded on day 7 was considered to be the accurate value.
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Table 34. MIC-breakpoints (µg/ml) used for susceptibility testing of bacteria. Isolates with MIC-values 
higher than those presented in this table are considered resistant. 
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Penicillin - - - - - 2 0,125 0,125 -
Oxacillin - - - - - - 2 0,25 - 
Amoxicillin 16 16 8 - 16 - - - - 
Amox/clav. acid 16/8 - 8/4 - 16/8 8/4 4/2 4/2 - 
Cephalothin - - - - - 16 16 16 - 
Cefuroxime - - - - 16 - - - - 
Cefoperazone - - - - 32 - - - - 
Ceftiofur - - - - - - - - - 
Cefquinome - - - - 4 - - - - 
Cefotaxime 1 - - - - - - - - 
Imipenem 1 - - - - - - - - 
Streptomycin - 8 2000 - 32 - 16 16 - 
Gentamicin 8 8 500  8 - - - - 
Kanamycin - - - - 16 - 16 16 - 
Neomycin 16 8 - - 16 - 16 16 - 
Spectinomycin - - - - - - - - - 
Tetracycline 8 - - - 8 4 8 8 - 
Doxycycline 4 4 8 8 - - - - - 
Sulphamethoxazole 256 256 - - - - - - - 
Trimethoprim 8 - - - - - - - - 
Trim/sulphamethoxazole 2/38 8/152 - - 2/38 2/38 2/38 2/38 - 
Nalidixic acid 16 16 - - - - - - - 
Difloxacin - - - 2 - - - - - 
Enrofloxacin - - - 1 2 - - - - 
Ciprofloxacin 2 2 8 - - - - - - 
Chloramphenicol 16 16 16 - - - - - - 
Florfenicol 16 - - - - - - - - 
Nitrofurantoine - - 128 - - - - - - 
Vancomycin - - 16 - - - - - - 
Teicoplanin - - 16 - - - - - - 
Avilamycin - - 16 - - - - - - 
Bacitracin - - 128 - - - - - - 
Flavomycin - - 16 - - - - - - 
Quinu/dalfopristin - - 2 - - - - - - 
Virginiamycin - - 8 - - - - - - 
Erythromycin - 16 4 - - 0,5 4 4 - 
Tylosin - - - 8 - - - - 16 
Tilmicosin - - 32 16 - - - - - 
Lincomycin - - - - - 4 4 4 - 
Pirlimycin - - - - - 2 2 2 - 
Tiamulin - - - - - - - - 1 
Metronidazole - 4 - - - - - - - 
Salinomycin - - 4 - - - - - - 
 
 

